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ABBREVIATIONS LIST 
 
AML = acute myeloid leukemia  
Ann-V = annexin-V 
BM = bone marrow 
CDK = cyclin dependent kinase  
CR = complete remission 
CVD = cyclophosphamide, bortezomib, and dexamethasone 
DKK-1 = dickkopf-1 
DMSO = dimethyl sulfoxide 
DVD = liposomal doxorubicin, bortezomib, and dexamethasone 
ECM = extracellular matrix 
EFS = event free survival 
FACS = fluorescence-activated cell sorting 
FBS = fetal bovine serum 
FGF = fibroblast growth factor 
FTI = farnesyl-transferase inhibitors  
G-CSF = granulocyte colony-stimulating factor 
HDAC = histone deacetylase  
HDT  = High-dose therapy 
HGF = hepatocyte growth factor 
HHV = human herpesvirus 
HL = Hodgkin's lymphoma  
HSC = hematopoietic stem cell 
HSP = heat-shock protein  
IC50 = median inhibition concentration 
ICAM-1 = intercellular adhesion molecule-1 
IFN = interferon 
Ig = immunoglobulin 
IGF = insulin-like growth factor 
IL = interleukin 
i.p. = intraperitoneally 
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i.v. = intravenously 
MAPK = mitogen activated protein kinase 
MDS = myelodysplastic syndromes  
MGUS = monoclonal gammopathy of undetermined significance 
MIP-1 = macrophage inflammatory protein-1 
MM = multiple myeloma 
MP-1 = MEK partner 1 
mTOR = mammalian target of rapamycin  
MVD = mean vascular density 
NFκB = nuclear factor kappa B 
NK = natural killer 
NSCLC = non-small-cell lung carcinoma  
NTX = amino-terminal cross-linking telopeptide  
OAFs = osteoclast activating factors 
OPG = osteoprotegerin 
OS = overall survival 
PBS = phosphate-buffered saline 
PDGFR = platelet-derived growth factor receptor 
PFS = progression free survival 
PI = propidium iodide 
p.o. = per os  
RANKL = receptor-activating of NF-B ligand 
ROTI  = related organ impairment 
RVD = lenalidomide, bortezomib and dexamethasone 
SCF =stem-cell factor 
SDF-1 = stromal cell-derived factor-1 
SMM = smoldering myeloma 
SRE  = skeletal related event 
TGF-β = transforming growth factor-β 
TKR = tyrosine-kinase receptors 
TNF = tumor necrosis factor 
TRAIL = TNF-related apoptosis-inducing ligand  
UPR = unfolded protein response 
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VAD = doxorubicin, vincristine and intermittent high-dose dexamethasone 
VCAM-1 = vascular cell adhesion molecule-1 
VEGF = vascular endothelial growth factor 
VGPR = very good partial response 
VTD = bortezomib, thalidomide, and dexamethasone 
XTT = 2,3-bis[2-Methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxyanilide inner 
salt  
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SUMMARY 
 
Multiple myeloma (MM) is a clonal plasma cell disorder accounting for approximately 
10% of all haematological malignancies. MM development dramatically depends on 
plasma cell interactions with bone marrow (BM) microenvironment, which supports 
plasma cell growth, survival and drug resistance through cell-cell adhesion and release of 
a large number of growth factors, including interleukin-6 (IL-6) and vascular endothelial 
growth factor (VEGF). Some crucial pathogenetic events in MM, such as 
neoangiogenesis and osteolysis, are ignited inside BM by MM cells themselves. 
Although standard chemotherapy is usually effective in lowering the disease burden, 
complete remission is achievable only in a minority of patients, and clinical responses are 
rarely persistent. Recent studies showed that a significantly higher number of patients 
may achieve clinical major responses when treated with therapeutic schedules based on 
the use of anti-angiogenic or biological agents, such as thalidomide, lenalidomide and 
bortezomib, especially when employed in combination with dexamethasone. However, 
MM still remains an incurable disease. Therefore, the identification of new key targets is 
crucial for the development of innovative therapeutic strategies, which should have not 
only direct effects on MM cells, but also interfering effects on MM-supporting BM 
microenvironment. To this aim, the use of mouse models that may closely resemble 
human MM development are mostly useful to foresee the clinical effects in patients. 
Some kinds of murine MM, such as 5TMM, originate from spontaneously developed 
MM in elderly mice of C57BL/KalwRij strain. The characteristics of these models, 
including the localization of the MM cells in the BM, the presence of serum M-
component, the induction of osteolytic bone disease  and neo-angiogenesis in the BM, are 
similar to human MM. In this study, we examined the effects of several new drugs in 
different murine and human myeloma cell lines and we tested these molecules in vivo in 
the murine 5T33MM model.  
T8 induced a reduction in cell activity only for high concentrations of molecule, with IC50 
value of 4315 nM after 48 hours of incubation; for this reason it was not used for further 
studies. 
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As expected, N80 did not show any cytotoxic activity on treated cells as compared to 
controls. However, when tested in vivo for a preventive and curative treatment, N80 
showed immediate toxicity and reduction of the tumor burden. There were not differences 
in IgG2b levels in serum of mice treated with N80 using the therapeutical schedule as 
compared to controls, while the preventive schedule induced a statistically significant 
reduction in IgG2b levels. 
L9, N0 and N2 were able to inhibit the activity of MM cells in vitro. They appeared the 
most potent compounds, with nanomolar IC50 values, capable of reducing cell viability, in 
correlation with cell apoptosis in vitro. These molecules reduced the M-component and 
VEGF serum levels in vivo and eventually the tumor burden, although they did not 
modify significantly, with the treatment schedules employed, the overall survival in 
5T33vtMM model. 
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RIASSUNTO 
 
Il mieloma multiplo (MM) è un disordine clonale delle plasmacellule, che rappresenta 
approssimativamente il 10% di tutte le neoplasie ematologiche. Lo sviluppo del MM 
dipende dalle interazioni con il microambiente del midollo osseo (BM), che supporta la 
crescita, la sopravvivenza e la resistenza ai farmaci delle plasmacellule attraverso 
l’adesione cellula-cellula e il rilascio di un grande numero di fattori di crescita, come 
l’interleuchina-6 (IL-6) e il fattore di crescita dell’endotelio vascolare (VEGF). Alcuni 
eventi patogenetici cruciali nel MM, come la neoangiogenesi e l’osteolisi, sono indotti 
all’interno del BM dalle stesse cellule di MM. Nonostante la chemioterapia standard sia 
spesso efficace nel ridurre la malattia, la remissione completa è raggiungibile solo in una 
minoranza di pazienti e le risposte cliniche sono raramente persistenti. Studi recenti 
mostrano che un numero altamente significativo di pazienti può ottenere buone risposte 
cliniche con protocolli terapeutici basati sull’utilizzo di agenti anti-angiogenici o 
biologici, come la talidomide, lenalidomide e il bortezomib, specialmente quando 
utilizzati in combinazione con il desametasone.  Nonostante ciò, il MM rimane ancora 
una patologia incurabile e perciò l’identificazione di nuovi obiettivi molecolari è cruciale 
per lo sviluppo di strategie terapeutiche innovative, che dovrebbero non solo avere effetti 
diretti sulle cellule neoplastiche, ma anche indiretti agendo sul microambiente midollare 
che supporta il MM. A questo scopo, l’utilizzo di modelli murini con un microambiente 
di sviluppo della malattia molto simile a quello umano risulta utile per prevedere gli 
effetti clinici nei pazienti. Tra questi, il 5TMM è di particolare interesse, in quanto 
origina da un MM sviluppato spontaneamente in topi anziani del ceppo C57BL/KalwRij. 
Le caratteristiche di tale modello, che comprendono la localizzazione midollare delle 
cellule di MM, la presenza della componente monoclonale nel siero, l’induzione di 
osteolisi e la neoangiogenesi nel midollo, lo rendono molto simile al MM umano. In 
questo studio, sono stati esaminati gli effetti in vitro di diversi nuovi farmaci in fase di 
sviluppo della Ditta Novartis su linee cellulari umane e murine e sono state testate queste 
molecole in vivo nel modello 5T33MM.  
La molecola T8 induce una riduzione dell’attività cellulare solo per alte concentrazioni, 
con un valore di IC50 di 4315 nM dopo 48 ore di incubazione; per questa ragione non è 
stato utilizzato negli studi successivi. 
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Come atteso, la molecola N80 non mostra alcuna attività citotossica sulle cellule trattate 
rispetto ai controlli. Comunque, quando è stato testata in vivo per un trattamento 
preventivo e curativo, è stata dimostrata un’immediata tossicità e la riduzione del carico 
tumorale. Non si evidenziano differenze nei livelli di IgG2b monoclonale nel siero dei 
topi trattati con N80 utilizzando il protocollo terapeutico rispetto ai controlli, mentre il 
protocollo preventivo induce una riduzione statisticamente significativa nei livelli di 
IgG2b. 
L9, N0 e N2 sono in grado d’inibire l’attività delle cellule di MM in vitro. Si sono 
dimostrati i composti più potenti, con valori nanomolari di IC50 e in grado di indurre una 
riduzione della vitalità cellulare, correlata con l’apoptosi cellulare in vitro. Queste 
molecole riducono la produzione della componente monoclonale e i livelli sierici di 
VEGF in vivo. Quindi, queste molecole sono in grado di ridurre il carico tumorale, 
sebbene non modifichino la sopravvivenza dei topi nel modello 5T33vtMM con gli 
attuali protocolli terapeutici utilizzati. 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 
 
 
 
 
 
10 
 
INTRODUCTION 
1. MULTIPLE MYELOMA 
 
1.1 Epidemiology  
Multiple myeloma (MM) is a monoclonal plasma cell disorder determined by a 
clonogenic, neoplastic plasma cells accumulation inside the bone marrow (BM). It is 
generally characterized by the presence of an entire or fragmented monoclonal 
immunoglobulin (Ig) in the serum and/or urine and bone osteolytic lesions 
[1,2]
. 
MM accounts for approximately 1% of all cancers and 10% of hematological 
malignancies in white populations, with approximately 23,000 new cases diagnosed each 
year in Europe 
[1-3]
. Male/female ratio is about 2:1. The incidence is higher in black 
people and lower in Asians than in white people. The incidence increases along age 
(median age at diagnosis: 67 years) and only about 3% of patients are younger than 40 
years 
[4]
. MM incidence has been increasing in many countries because of improved 
diagnostic accuracy and increasing risk factors, such as obesity 
[5]
. Median survival after 
conventional treatment is 3-4 years; high-dose treatment followed by autologous stem-
cell transplantation can prolong median survival up to 5-7 years. Novel drugs used alone 
and in combination with existing treatments are currently tested to further improve 
survival. 
MM is characterized by a number of typical features 
[2,6-8]
: 
 clonal accumulation of clusters of long-living, poor-proliferating malignant 
plasma cells inside the bone marrow; 
 presence of monoclonal proteins, i.e. paraproteins (usually IgG, IgA and IgD), 
released by malignant plasma cells in blood and/or urine (Bence Jones 
proteinuria); 
 reduction in the normal levels of Ig (hypogammaglobulinemia). 
MM presentation is quite variable, as it may be diagnosed both in asymptomatic patients 
and in patients with life-threatening clinical events. Clinical features are characterized by 
multiple symptoms and organ disfunctions 
[3,6-8]
: 
 lytic bone disease: BM invasion by MM cells and bone destruction cause bone 
pain, particularly in weight-bearing bones, pathological fractures secondary to 
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lytic bone lesions and hypercalcemia, that often dominates the clinical feature. 
The interactions between plasma cells and BM microenvironment determine the 
activation and proliferation of osteoclasts and suppress osteoblast activity, thus 
causing an imbalance between bone resorption and bone formation 
[9]
. Up to 80% 
of MM patients refer bone pain at diagnosis and more than 70% of patients 
develop pathological fractures during the disease course 
[10]
; 
 hypercalcemia: it is due to increased bone resorption; 
 renal insufficiency: it may be secondary to light-chain and heavy-chain renal 
deposition, dehydration, hypercalcemia, hyperuricemia, direct plasma cells 
infiltration of the kidney. Up to 20% or 30% of MM patients have some form of 
renal impairment at diagnosis 
[11,12]
; 
 susceptibility to infections: MM patients are immunosuppressed and particularly 
susceptible to bacterial infections. This immunodeficiency is mainly caused by 
abnormal Ig production and impairment of the primary immune response. 
Pneumonias and urinary tract infections are mostly frequent 
[13,14]
; 
 anemia: it is a common complication of MM, caused by the abnormal iron 
utilization, abnormally low serum erythropoietin levels, decreased response to 
erythropoietin, hemolysis or BM involvement; 
 neurological symptoms: the most frequent neurological features include spinal 
cord compression, radiculopathy, peripheral neuropathy, cerebral disorders and 
cranial nerve involvement 
[15]
; 
 alterations in coagulative activity: the direct interaction of monoclonal Ig with 
hemostatic mechanisms may lead to the development of either hemorrhagic or 
thrombotic events. Bleeding may be present in 15-30% of the patients, while the 
baseline thrombotic risk is approximately 3% 
[16,17]
. Rarely, MM can present with 
hyperviscosity syndrome or cryoglobulinemia causing vascular problems, as well 
as renal or gastrointestinal disorders 
[18]
; 
 amyloidosis: amyloid deposition mainly occurs at renal and cardiac level. 
 
1.2 Stages of multiple myeloma 
Epidemiologic studies have shown that at least one-third of MM cases is the evolution of 
a pre-existing monoclonal plasma cell disorder, i.e. monoclonal gammopathy of 
undetermined significance (MGUS). This suggests that two types of MM exist: MM 
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secondary to MGUS and primary, de novo MM 
[5]
. The malignant transformation of 
MGUS to MM seems to be a multi-step transformation process, in which genetic 
changes, BM angiogenesis, various cytokines related to bone disease and possibly 
infectious agents may be involved 
[1,19]
. (Figure 1). 
 
 
Figure 1: biological events related to MM progression [20] 
 
MGUS is typically asymptomatic and stable. Cells are immortalized but not transformed, 
and do not accumulate or cause bone destruction. In MGUS there is a lower 
intramedullary tumor-cell content (tumor cells are no more than 10% of the mononuclear 
cells in the BM) and lower monoclonal Ig production (≤ 30 g/L IgG or ≤ 20 g/L IgA). 
MGUS is present in 1% of adults and progresses to malignant MM at 1% per year rate 
[21]
. At the time of diagnosis, the risk of progression to MM cannot be determined, but 
different parameters are useful, such as the dose and type of serum monoclonal protein 
(higher risk in presence of IgD or IgA rather than IgG), percentage of BM plasma cells 
and abnormal serum free light chain (FLC) ratio. 
Non-symptomatic smouldering MM (SMM) is a disease variant with stable 
intramedullary tumor cell content of more than 10%, but no osteolytic lesions or other 
complications of malignant MM. MGUS and SMM can switch into intramedullary MM 
accumulating inside BM microenvironment and causing bone destruction via cytokine-
induced increased osteoclast activity. 
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Further progression of MM is associated with increasingly severe secondary features 
(lytic bone lesions, anemia, immunodeficiency, renal impairment) and extramedullary 
plasma cell invasion, i.e. plasma cell leukemia, which is secondary or primary, depending 
on whether intramedullary myeloma has been previously recognized or not 
[3,10,21]
. 
 
1.3 Etiology 
MM etiology remains unknown. Risk factors include chronic immune stimulation, 
autoimmune disorders, exposure to ionizing radiation and other environmental factors, 
such as pesticides, herbicides and dioxin. A number of viruses has been implicated in the 
pathogenesis of MM. Patients with HIV have 4.5 fold increased risk of developing MM, 
although the precise mechanism still remains unclear. HHV-8 (human herpesvirus-8) 
infection has been demonstrated in BM stromal cells in MM patients and could be 
associated with the development and progression of the disease. HHV-8 has also been 
identified in stromal cells of other plasma cells disorders, such as MGUS and primary 
systemic amyloidosis, implying a potential casual association 
[3]
. 
Genetic factors are also important and different studies analyze the genetic background of 
the malignant MM cell clone. Studies on the chromosome content suggest two molecular 
pathways of MM pathogenesis: a non-hyperdiploid (or hypodiploid) pathway with high 
incidence of 5 recurrent IgH translocations and loss of chromosome 13/13q14; and a 
hyperdiploid pathway with multiple trisomies. Non-hyperdiploid abnormalities are 
associated with reduced life-span and high-risk translocations of IGHR t(4;14) or 
t(14;16)), partial or complete loss of chromosome 13 and partial loss of chromosome 17. 
By contrast, hyperdiploid abnormalities caused by multiple trisomias, and low frequency 
of monosomy or deletion of chromosome 13 and translocation of IGHR are associated 
with improved outcome. 
Primary reciprocal chromosomal translocations occur most frequently at IGHR on 
chromosome 14, which is usually juxtaposed to CCND1, CCND3, MAF, FGFR3, 
WHSC1 and MAFB genes. For example, the t(4;14) translocation generates a constitutive 
activation of the oncogenic tyrosine-kinases receptor fibroblast growth factor receptor3 
(FGFR3), with subsequent phosphorylation of the antiapoptotic signal transducer and 
activator of transcription 3 (STAT3) signaling pathway, which promotes cell survival. 
Secondary translocations and gene mutations are complex karyotypic abnormalities of 
MYC, activation of NRAS, KRAS and FGFR3 mutations, inactivating mutations or 
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deletions of TP53, RB1 and PTEN, and inactivation of cyclin-dependent kinase inhibitors 
CDKN2A and CDKN2C 
[4,22,23]
. 
Epigenetic activation is another mechanism that may influence the development of MM 
cell clone. For example, SHPI, a native regulator of the Jak/STAT signaling pathway, is 
hypermethylated in 80% of MM patients and associated with constitutive STAT3 
phosphorylation. Telomeres, specialized nucleoprotein which protect against fusion and 
degradation of linear chromosomes, represent another potential therapeutic target. In MM 
cells the mean telomere length is markedly shorter than in peripheral granulocytes and 
lymphocytes 
[24]
, and telomerase activity is increased in MM cells as compared to normal 
plasma cells 
[22]
. 
 
1.4 BM microenvironment in MM 
Plasma cells represent <1% of BM mononuclear cells. They derived from activated B 
cells in the germinal center of the lymph nodes: B cells with a high affinity antigen 
receptor (Ig) are selected by antigen through mutations of the Ig variable genes and then 
induced to become either memory B cells or antibody-producing plasmablastic cells. The 
latter cells migrate rapidly to the BM where they can find additional survival and 
differentiation factors supporting their long-term survival and differentiation into plasma 
cells. Hallmarks of mature plasma cells are their large amounts of Ig secretion, high 
expression of the syndecan-1 proteoglycan that is not expressed on B cells and the lack of 
most B cell markers, except CD19 
[25]
. 
The role of BM microenvironment in MM pathogenesis has been thoroughly studied. In 
MM the balanced homeostasis between cellular, extracellular and liquid compartments 
within the BM is profoundly disrupted, resulting in lytic bone lesions, immune 
suppression and cytopenias. These effects are caused not only by the clonal expansion of 
MM cells in the BM, but also by the impact of tumor cells on the functions of other cells 
within the BM microenvironment. Direct cell-to-cell/cell-to-extracellular matrix (ECM) 
interactions or cytokines/growth factors modulate functions of different cells, including 
endothelial cells, osteoclasts, osteoblasts, fibroblasts and immune effector cells, which in 
turn promote tumor-cell growth, survival, migration and drug resistance. BM 
angiogenesis in MM is tightly regulated by pro- and anti-angiogenic factors and BM 
microvascular density (MVD) is increased and correlates with disease progression and 
poor prognosis. (Figure 2) 
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Figure 2: Interaction between plasma cells and bone marrow in multiple myeloma [26] 
 
Increasing knowledge about BM microenvironment in MM can contribute to the design 
of new biological treatment regimens aimed at targeting not only MM cells, but also MM 
cell-stromal cell interactions and BM microenviroment (Figure 3) 
[22,27]
  
 
 
Figure 3: Interactions of neoplastic plasma cell and microenviroment are targets for new drug. [28] 
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There are different ways of interaction between malignant MM clone and BM 
microenvironment: 
 interactions with the extracellular matrix and other cells within the BM 
microenvironment: MM plasma cells adhere to the extracellular matrix proteins 
and BM stromal cells through a number of adhesion molecules, such as 1-
integrin family with several very late antigens (VLA, VLA-4, VLA-5 and VLA-
6), as well as intercellular adhesion molecule 1 (ICAM-1) and vascular cell 
adhesion molecule 1 (VCAM-1). The main molecules regulating plasma cell 
homing into the BM and binding to extracellular matrix are CD44, VLA-4, VLA-
5, LFA-1 (CD11a), CD56, CD54 (ICAM-1), syndecan-1 (CD138) and MPC-1 
(Monocyte chemotactic protein-1) 
[29]
. This binding induces cell-adhesion-
mediated drug resistance and secretion of several cytokines by both MM plasma 
cells and BM stromal cells. 
In particular, MM cells express 1 integrins, including VLA-4 and VLA-5, that 
mediate MM cell adhesion to endothelial cells, fibroblasts and ECM proteins, 
such as fibronectin and laminin. Adhesion enhances MM cell growth and survival 
and confers protection against drug-induced apoptosis. For example, MM cell 
adhesion to fibronectin protects tumor cells from DNA-damaging drugs (such as 
anthracyclines and alkylating agents) by inducing cell-adhesion-mediated drug 
resistance, with reversible G1-arrest and increased p27kip1 levels. Moreover, MM 
cells express also v3-integrins that mediate the binding to vitronectin and 
fibronectin, stimulating the production and release of metalloproteinase 2 and 9, 
both promoting tumor-cell invasion and spread. Ongoing studies are testing novel 
molecules, that are able to alter adhesive interaction among MM cells, accessory 
cells and ECM to increase anti-MM activity and reduce drug-resistance 
[22]
; 
 cytokines and growth factors: tumor cells activate the stroma, that triggers the 
paracrine and autocrine production and secretion of a variety of cytokines and 
growth factors into the BM-microenvironment, including IL-6, IGF-1 (insulin-like 
growth factor), VEGF, TNF-α (tumor necrosis factor-, SDF-1 (stromal cell- 
derived factor-1, TGF- (transforming growth factor-), bFGF (basic fibroblast 
growth factor), MIP-1 α (macrophage inflammatory protein-1), SCF (stem-cell 
factor), HGF (hepatocyte growth factor), MP-1 (MEK partner 1), osteoprotegerin 
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(OPG), RANKL (receptor-activating nuclear factor kappa-beta ligand), IL-1, IL-
3, IL-10, IL-15, IL-21, Ang-1 and matrix metalloproteinases (e.g. MMP-2 and 
MMP-9). These cytokines trigger signaling pathways (NF-kB, 
RAF/MEK/MAPK; PI3K/AKT and JAK/STAT pathways), thus promoting cell 
proliferation and preventing apoptosis (IL-6, TNF-, IGF-I, IL-1, VEGF), 
inducing angiogenesis (VEGF, FGF, HGF), osteoclast activity (IL-1, RANKL, 
HGF) and immunodeficiency (TGF-β, VEGF) [23]. 
In particular: 
o IL-6: it is the major growth and survival factor for MM cells. It has 
pleiotropic effects on hematopoietic and non-hematopoietic cells, induces 
purified B cells to differentiate into Ig-secreting plasma cells, and acts as a 
growth factor for MM. Thus, IL-6 mediates the expansion of plasmablastic 
cells and their malignant counterparts 
[19,25]
. The evidence that IL-6 is 
involved in MM pathogenesis was established by the following 
experimental and clinical findings: 
 serum levels of IL-6 and soluble IL-6R are increased in patients 
with MM in association with poor prognosis 
[30]
; 
 antibodies against IL-6 block MM cell proliferation [31]; 
 injection of anti-IL-6 monoclonal antibody inhibits MM cell 
proliferation in patients with terminal disease if the antibody is 
injected at concentrations blocking completely the large amount of 
IL-6 produced in vivo 
[32]
; 
 BM microenvironment of MM patients, consisting mainly of 
monocytes, myeloid cells and stromal cells, overproduces IL-6 
[33,34]
. IL-6 production is mediated by soluble factors, cytokines 
and by intercellular interactions; 
 survival of cell lines, obtained from patients with extramedullary 
proliferation, depends on the addition of exogenous IL-6 [35,36]. 
IL-6 is predominantly produced and secreted by BM stromal cells and 
osteoblasts, and correlates with MM tumor cell mass, disease stage and 
prognosis 
[37,38]
. MM cells also shed the soluble form of IL-6 receptor 
(sIL-6R, gp80), which can amplify their response to IL-6. 
[3]
. In fact, about 
50% of serum IL-6 is bound to gp80. The complex of IL-6/sIL-6R is much 
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more powerful than IL-6 alone in stimulating malignant plasma cells 
through the gp130 receptor signal-transduction pathway 
[37]
. IL-6 triggers 
activation of MEK/MAPK-, JAK/STAT3- and PI3K/AKT- signaling 
pathways 
[30,39]
. IL-6 triggered JAK/STAT3 pathway induces 
upregulation/activation of antiapoptotic proteins Mcl-1 and BclXL, Pim1 
and c-Myc. Besides MM cell growth and survival, IL-6 also triggers drug 
resistance. However, many cell lines grow independently of IL-6 and 
different therapeutic approaches targeting IL-6 have not induced responses 
in phase I clinical trials. Taken together, these data show that IL-6 is 
crucial, but not the only factor in MM pathogenesis 
[27]
; 
o IGF-1: it is a survival and proliferation factor for most myeloma cell lines 
[40]
. In MM, IGF-1 induces tumor cell growth, survival and migration. It is 
mostly produced by the liver, but also by osteoblasts in the bone matrix, 
where myeloma cells survive and proliferate in vivo. IGF-1 serum levels 
are predictive of poor survival in patients with MM, although they are not 
increased 
[25]
. IGF-1 induces the activation of the PI-3 kinase (PI3K) 
pathway, that can induce the phosphorylation of the anti-apoptotic AKT 
protein and MAPK 
[41,42]
. Different substrates of PI3K/AKT pathway are 
involved 
[43]
, such as: Bad (pro-apoptotic protein: after the 
phosphorylation by AKT, Bad sequestration by the 14-3-3 protein 
prevents its migration to the mitochondrial membrane); P70S6-kinase (its 
phosphorylation by AKT induces its kinesic activity to ribosomial subunit 
40S, with a consequent increase of protein synthesis); Forkhead proteins; 
Glycogen synthase kinase-3 (GSK-3, that is inactivated) and NF-B; 
o members of the TNF superfamily: it includes SDF-1CD40, BAFF and 
APRIL. SDF-1and its cognate receptor CXCR4 are expressed in the BM 
of MM patients. SDF-1is primarly produced by BM stromal cells, but 
also by MM cells; it upregulates rapidly and transiently VLA-4-mediated 
MM cell adhesion to both fibronectin and VCAM-1. Furthermore, SDF-
1promotes proliferation, induces migration and protects against drug-
induced apoptosis in MM cells through MAPK, NF-B and AKT-
mediated pathways. In addition, SDF-1upregulates secretion of IL-6 and 
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VEGF in BM stromal cells and is a critical regulator of MM cell migration 
and homing.  
CD40 is expressed by antigen-presenting cells, T cells and B cell 
malignancies, including MM. Functionally, it mediates p53-dependent 
increases in MM cell growth, PI3K/AKT/NF-B- dependent MM cell 
migration and triggers VEGF secretion. Moreover, CD40-activated MM 
cells adhere to fibronectin and are protected against apoptosis induced by 
irradiation and doxorubicin. 
TNF-, secreted mainly by macrophages, poorly triggers MM cell 
proliferation, survival and drug resistance. However, it markedly 
upregulates secretion of IL-6 by BM stromal cells and induced NF-B-
dependent expression of different molecules (e.g. CD49d, CD54), thus 
resulting in increased specific binding of MM cells to BM stromal cells 
and consequent induction of IL-6 transcription and secretion, as well as 
drug-resistance 
[22]
. 
BAFF or B lymphocyte stimulator is normally expressed by monocytes, 
macrophages, dendritic cells (DCs), T cells and BM stromal cells, and 
exists as both membrane-bound and cleaved soluble protein. In MM, both 
tumor cells and BM stromal cells express high levels of BAFF and 
APRIL, as well as their receptors. Functionally, BAFF and APRIL protect 
MM cells from apoptosis induced by IL-6 deprivation and promote MM 
cell growth and adhesion to BM stromal cells. These processes are 
mediated by NF-B-, PI3K/AKT- and MAPK- pathways [27]; 
o FGF: although serum levels of FGF2 are increased in MM, there is no 
direct evidence so far that its expression plays a role in the survival or 
proliferation of human myeloma cells. FGFs likely play an important role 
in myeloma biology: in fact, FGFs bind syndecan-1 and activation of 
FGFR3 may induce the PI3-K/AKT pathway that is critical for myeloma 
cell survival and proliferation 
[44]
; 
o VEGF: various growth factors belong to the VEGF family: VEGF-A, 
VEGF-B, VEGF-C, VEGF-D, VEGF-E and placenta growth factor 
(PIGF). VEGF is secreted by several MM cell lines and is present in 
patient plasma. VEGFR-1 is highly expressed by MM cells, consistently 
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with autocrine signaling 
[45,46]
. Specifically, VEGF triggers Flt-1 
phosphorylation and activation of MEK/ERK and PI-3K/PKC- signaling 
cascades in MM cell lines and patient cells, thus promoting modest 
proliferation and pronounced migration, respectively 
[29]
. VEGF also 
influences also osteoblasts, NK cells, monocytes and endothelial 
progenitors. In fact, it stimulates BM angiogenesis and inhibits antigen-
presenting functions of DCs, thus contributing to immune suppression in 
MM 
[2]
; 
o IL-10: it enhances proliferation of freshly isolated MM cells in short-term 
BM culture. Moreover, the growth of MM lines is supported by IL-10 
[19,25]
; 
 neoangiogenesis: the importance of tumor angiogenesis in the evolution of solid 
tumors and hematological malignancies is well established: the increase in MVD 
within BM microenvironment is considered an important prognostic factor for 
median overall survival (OS) and event-free survival (EFS) at the time of initial 
diagnosis, and correlates with disease progression and poor prognosis 
[47,48]
. The 
main angiogenic factor involved is VEGF that is secreted by several MM cell 
lines and is present in MM BM aspirates. 
[15]
. There is a hypothetical paracrine 
loop for angiogenesis and tumor growth in the BM of MM patients: Plasma cells 
secrete VEGF-A, which induces proliferation and chemotaxis in endothelial cells 
through VEGFR-2, a VEGF-A receptor expressed by those cells. VEGF-A acts 
also through its receptor VEGFR-1, expressed by stromal cells, inducing their 
proliferation. Activation of these cells results in VEGF-C and VEGF-D 
production that stimulates malignant plasma cell growth via VEGFR3. Finally, 
the VEGF–VEGFR-2 interaction by endothelial cells increases IL-6 levels, 
creating another paracrine loop for plasma cell growth 
[49]
; 
 myeloma bone disease and osteoblastic niche (Figure 3) one of the earlier 
symptom in MM is the excessive bone resorption. Histomorphometric analysis of 
bone biopsies from MM patients shows that osteolytic bone lesions are due to the 
unbalanced bone remodeling that increases osteoclastic resorption and lowers 
bone formation. As a result, MM bone lesions are highly destructive and appear as 
areas of extensive demineralization at x-ray scan 
[50]
. In particular, there is a 
significant increase in both the recruitment of new osteoclasts and osteoclast 
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activity in close contact with myeloma cells. This suggests that bone disease 
results from local production of osteoclast activating factors (OAFs), such as 
RANKL/OPG system and the chemokine MIP-1, secreted by either myeloma cells 
or BM stromal cells. RANKL is expressed by osteoblasts and binds to its receptor 
(RANK) present on osteoclasts, thus triggering differentiation and activation 
signals in osteoclast precursors and promoting bone resorption. OPG 
(osteoprotegerin) is the natural antagonist of RANKL and its expression regulates 
osteoclast activity and bone resorption, thus preserving bone integrity. Different 
studies have shown that myeloma cells are able to induce increased RANKL 
expression and decreased OPG production in the BM environment. In BM 
biopsies from MM patients, RANKL is overexpressed in stromal cells in the 
interface between MM and normal BM elements, and also in myeloma cells. 
Several other OAFs, including IL-1, IL-6 and TNF-α, are overproduced by BM 
stroma in response to MM. However, the addition of blocking antibodies against 
these molecules in co-cultures does not prevent RANKL upregulation. 
In addition, in BM of MM patients decreased production of OPG occurs through 
two mechanisms: i. a decrease in OPG production by stromal cells is directly 
induced by MM cells; ii. myeloma cells internalize and degrade OPG within the 
lysosomal compartment 
[10]
.  
 
 
Figure 3:  myeloma bone disease. 
[9]
 
 
22 
 
Denosumab is a fully human monoclonal antibody against RANKL. In a recent 
study, 1776 adult patients with solid tumors or MM (10% of the total patients), 
not previously treated with intravenous bisphosphonates, were randomized to 
receive either subcutaneous denosumab 120 mg or intravenous zoledronic acid 
every 4 weeks. Denosumab produced similar results regarding the delay of the 
first onset or subsequent of skeletal related event (SRE) as compared to 
zoledronic acid; in addition, Denosumab reduced rapidly and significantly (>80% 
in the first month) urinary amino-terminal cross-linking telopeptide of type I 
collagen (NTX) levels, a marker of bone resorption. 
[51]
. 
The other system involved in myeloma-induced bone disease is the chemokine 
MIP-1. MIP-1 and are overexpressed and secreted by myeloma cells. MIP-1 
belongs to the RANTES family and acts as chemoattractant and activator of 
monocytes. Both osteoclast precursors and stromal cells express the chemokine 
receptor for MIP-1 and (CCR5) and MIP-1/CCR5 interaction induces 
expression of RANKL in stromal cells. Furthermore, CCR5 is expressed by MM 
cells; therefore, MIP-1 and may act on MM cells in both autocrine and 
paracrine fashion. In fact, MIP-1 triggers migration and signaling cascades 
mediating survival and proliferation in MM cells. MIP-1 and are potent 
modulator of hematopoiesis: MIP-1 inhibits early erythropoiesis and MIP-1 
increases apoptosis in pre-B cells. Therefore, MIP-1 and MIP-1 are pleiotropic 
chemokines that play important roles in the pathogenesis of several clinical 
features of MM, including not only destructive bone lesions, but also suppression 
of erythropoiesis, B lymphopoiesis and immunoglobulin production. 
RANKL/OPG and MIP-1 pathways enhance osteoclast formation and activity 
through osteoblasts, although studies in mice demonstrate the importance also of 
the myeloma-osteoclast loop for sustaining the disease progression through a still 
unclear mechanism. 
[10]
.  
 
Recent research has identified other factors that regulate osteoblast function and 
help maintaining skeletal homeostasis. Specifically, the dickkopf-1 (DKK-1) 
protein plays an important role in regulating bone homeostasis; DKK-1 
overexpression by myeloma cells is involved in bone loss, leading to osteolytic 
bone lesions in MM patient. In fact, DKK-1 inhibits the differentiation and 
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maturation of mesenchymal stem cells into bone-producing osteoblasts, thus 
promoting osteoclast activation. Treatment with DKK-1 neutralizing antibody 
prevents bone loss, increases the number of osteoblasts and inhibits MM cell 
proliferation in a mouse model of MM. Clinical evidence for the role of DKK-1 in 
MM is emerging. In a study by Tian E. et al. in 173 patients with newly 
diagnosed MM, elevated DKK-1 levels in blood and BM correlated with the 
presence of bone lesions. In another study by Kaiser M. et al. in 184 patients with 
MM, high DKK-1 levels were associated with the presence and number of bone 
lesions, as well as with Durie–Salmon disease stage. Therefore, the available data 
support the concept of targeting DKK-1 to develop new therapeutic strategies for 
MM 
[50]
. 
Over the past two decades, the isolation and characterization of cellular and 
extracellular components of the skeletal matrix led to the development of 
biochemical markers that reflect either bone formation or resorption. Markers of 
bone resorption and formation are depicted in Tables 1 and 2. Measurement of 
bone turnover markers is non-invasive, cheap and, when applied and interpreted 
correctly, helpful in assessing bone disorders. 
However, factors that affect bone turnover and marker levels, including circadian 
rhythm, diet, age, gender, renal function and drugs, should be clearly defined and 
appropriately adjusted, whenever possible. It is also important to recognize that 
these biochemical measurements reflect whole-body bone turnover and give little 
information about the function of local changes in skeletal homeostasis 
[51]
. 
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Table 1: Markers of bone resorption 
 
Abbreviations: ELISA, enzyme-linked immunosorbent assay; HPLC, high-performance liquid 
chromatography; MMP, matrix metalloproteinase; RIA, radioimmunoassay. 
According to the bone marker nomenclature by the Committee of Scientific Advisors of the 
International Osteoporosis Foundation. 
 
Table 2: Markers of bone formation 
 
Abbreviations: ELISA, enzyme-linked immunosorbent assay; RIA, radioimmunoassay; IRMA, 
immunoradiometric assay. 
According to the bone marker nomenclature by the Committee of Scientific Advisors of the 
International Osteoporosis Foundation. 
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1.5 Disease management  
MM remains an incurable disease and, therefore, new therapeutical approaches are 
needed to improve the patient outcome (Figure 4). Increasing knowledge on the biology 
of MM is already contributing to the design of new drugs targeting cellular proteins or 
pathways involved in the pathophysiology of the disease. 
 
 
Figure 4. A continuous improvement in response is seen with the combination of newer agents. [52] 
 
When to treat 
Although novel agents has been employed for the early treatment of smouldering 
myeloma, there is no evidence yet that such approach improves survival in patients with 
no symptoms and stable disease. Up to 25% of smoldering myeloma patients does not 
require active treatment for 10 to 15 years, although the majority undergoes disease 
progression during that time. Thus, the employment of the maximum efficacy of the 
drugs only in symptomatic patients still remain preferable, as some data suggest that early 
intervention might select more aggressive subclones of myeloma. 
Smoldering myeloma patients require frequent monitoring to identify the need of 
treatment before organ damage is evident, although the use of certain supportive 
therapies, such as bisphosphonates for osteopenia, is justified in selected patients 
[52]
. 
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Recommendations 
• Chemotherapy is only indicated in patients with symptomatic MM on the basis of the 
presence of related organ impairment - ROTI (Grade A recommendation; level of 
evidence Ib); 
• patients with asymptomatic myeloma should be monitored under the supervision of a 
Consultant Hematologist. These patients should entry into clinical trials if available 
(Grade C recommendation; level of evidence IV); 
• monitoring of patients with asymptomatic myeloma should include regular (every 3 
months) clinical assessment of the emergence of ROTI and measurement of serum and 
urinary M-protein (and SFLC, when indicated). Repeated BM examination and skeletal 
imaging should be considered prior to start the treatment (Grade C recommendation; 
level of evidence IV) 
[53]
. 
 
Therapeutic targets 
Novel therapeutic cellular targets are MM cells, BM stromal cells, endothelial cells, 
genes (e.g. FGFR3), cytokines, growth factors and specific signaling pathways (KRAS, 
RAF1, MAPK2K1, PI3K and AKT, JAK and STAT3, PRKC, NF-B and WNT). For 
example, thalidomide, lenalidomide and bortezomib have been shown to overcome the 
supportive effects of BM microenvironment. Other preclinical drugs have been designed 
to inhibit either transport of ubiquitinated proteins to the aggresome (tubacin) or histone 
deacetylase (LBH589 - vorinostat). These drugs are capable of inducing synergistic 
cytotoxic effects against MM cells in BM. Additional drugs with increased potency and 
reduced adverse effects (e.g. antiangiogenic and endothelial-targeting drugs) are more 
active when combined with conventional or novel agents for MM. 
 
Newly-diagnosed disease 
High-dose therapy (HDT) plus autologous stem cell transplantation is considered the 
standard of care for front-line treatment of < 65 year old MM patients. New drugs have 
been investigated in various combinations as induction therapy. In particular: 
 
 thalidomide has been used for MM treatment because of its anti-angiogenic, direct 
pro-apoptotic and G1 growth arrest-inducing effects, even in drug-resistant 
myeloma cells. It abrogates the increased secretion of IL-6 and VEGF and 
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stimulates autologous NK cell-mediated anti-myeloma immunity. Common side 
effects of this drug in patients with all stages of disease are deep vein thrombosis, 
constipation, peripheral neuropathy and fatigue, which often restrict dose and 
treatment duration to the detriment of drug effectiveness. Different trials have 
shown better responses by combining thalidomide and dexamethasone or 
thalidomide, dexamethasone and doxorubicin, as compared to conventional 
chemotherapy (e.g. high-dose dexamethasone or VAD – doxorubicin, vincristine 
and intermittent high-dose dexamethasone); 
 lenalidomide is an immunomodulatory drug, more powerful than thalidomide and 
without sedative and neurotoxic adverse effects. The most common side-effect is 
myelosuppression, which is usually reversible with dose reduction and growth 
factor support. Clinical trials have suggested that lenalidomide, in combination 
with low-dose dexamethasone, leads to better  progression free survival (PFS)  
and OS rates. Moreover, combined lenalidomide and dexamethasone improve 
response as compared to conventional high-dose dexamethasone alone. Risk of 
deep vein thrombosis is an important side effect and prophylaxis have to be used; 
 bortezomib is a dipeptide boronic acid that inhibits the function of the 26S 
proteasome complex. It determines the accumulation of misfolded/damaged 
proteins and cell apoptosis mediated by caspase 8 and 9, inhibits MM cell growth, 
survival and migration and targets MM microenvironment. Inhibition of NF-B 
through accumulation of IB plays a key role in this process. Bortezomib induces 
apoptosis in drug-resistant MM cells, and inhibits both secretion of cytokines 
(such as IL-6) and binding of MM cells to the BM microenvironment. The anti-
angiogenic effect of Bortezomib is another potential mechanism of its anti-MM 
activity. Most common side-effects are peripheral neuropathy, transient 
thrombocytopenia, fatigue and gastrointestinal disorders 
[2,4,5,27]
. 
 
Choice of initial drug therapy 
Although successful and long-term remission has been achieved in many transplantation-
eligible patients by using limited treatment regimens (thalidomide + dexamethasone, 
bortezomib + dexamethasone, and lenalidomide + dexamethasone), complete and very 
good partial response (VGPR) rates can be substantially increased by combining 3 or 4 
different drugs. Preliminary results from ongoing phase 3 randomized trials show 
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improved initial response rates and increased frequency of complete remission (CR) after 
induction therapy in patients randomized to receive bortezomib and dexamethasone 
versus VAD chemotherapy, and in patients randomized to receive bortezomib, 
thalidomide and dexamethasone versus thalidomide and dexamethasone alone. These 
higher response rate was followed by higher frequency of CR after transplantation and, at 
least in preliminary reports, improved PFS. As durable CR and PFS appear to be valuable 
surrogates for long-term outcome, multiple drug combination therapies have been applied 
to younger patients suitable for high-dose therapy approaches. 
The earliest reports of 3 drug-therapeutical schedules came from the combination of 
bortezomib, thalidomide, and dexamethasone (VTD) and the encouraging results have 
been confirmed by using either lenalidomide, bortezomib and dexamethasone (RVD), or 
liposomal doxorubicin, bortezomib, and dexamethasone (DVD), or cyclophosphamide, 
bortezomib, and dexamethasone (CVD). 
Although response rates are clearly improved with new drug combinations, it is difficult 
to prove OS advantage considering the large numbers of patients and the long duration of 
follow-up required. Clinical studies with OS as endpoint are further complicated by the 
availability of a large number of effective salvage therapies. Nevertheless, RVD, CVD, or 
VTD are the most commonly used clinical trials so far. Consequently, VAD-based 
regimens or single-agent dexamethasone are less and less used, and even the simple 
combination of thalidomide and dexamethasone may be considered suboptimal therapies. 
Refractory or progressive disease is now uncommon when using multidrug combinations 
with overall response rates exceeding 90% in almost all recent studies. However, high-
dose melphalan should be considered for truly refractory patients, as this group of 
patients may benefit from this approach 
[52 ]
. 
 
Summary of treatment recommendations 
 
General (all Grade C recommendations; level IV evidence) 
• Chemotherapy prescribing should be undertaken by an experienced clinician with input 
from a chemotherapy-trained pharmacist; 
• SPC recommendations for dose adjustments of chemotherapeutic drugs and use of G-
CSF support should be followed wherever possible; 
• doses should be appropriately calculated to preserve renal and liver functions; 
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• patients with cytopenias at baseline, due to limited BM hematopoiesis, require more 
frequent monitoring and dose adjustment; 
• all patients should be considered for enrolment into clinical trials; 
• therapy choice should consider patient’s preference, co-morbidities and toxicity. 
 
Specific treatment recommendations for induction therapy prior to HDT 
• VAD or single agent dexamethasone should no longer be used routinely as induction 
therapy; 
• induction regimens should contain at least one novel agent; 
• induction regimens that are superior to VAD in terms of response rates include CTD, 
TAD, bortezomib/dexamethasone and PAD; 
• decisions regarding the most appropriate induction schedule require the assessment of a 
number of factors, such as renal function, thrombotic risk and pre-existing neuropathy, 
although some agents are not routinely funded as initial therapy in some countries (i.e. 
U.K. - the most clinical experience in the UK is based on the use of the CTD 
combination). 
 
Specific treatment recommendations for older and/or less fit patients in whom HDT is not 
planned  as initial therapy 
Induction therapy should consist of either thalidomide-containing regimens in 
combination with alkylating agent and steroid, such as MPT or CTDa (Grade A 
recommendation; level Ib evidence), or bortezomib in combination with melphalan and 
prednisolone (Grade A recommendation; level Ib evidence). 
 
Specific treatment recommendations for patients with plasma cell leukemia and rare 
myeloma subtypes (all are Grade C based on level IV evidence) 
• The use of initial treatment with bortezomib and autologous stem cell transplantation 
should be considered in responding patients with plasma cell leukemia; 
• IgD, IgE and IgM myeloma are associated with a poor outcome, but there are 
insufficient data to support specific alternative treatment strategies at this time 
[53]
. 
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How much treatment before stem cell transplantation? 
For the patient eligible for transplantation, autologous stem cell collection and 
transplantation after 4 to 6 cycles of induction therapy is recommended. However, as the 
stated goal of therapy is to maximize the depth and duration of remission, induction 
therapy can be continued in some patients in presence of evident response and 
tolerability. High-dose melphalan and stem cell transplantation are consolidation 
schedules after obtaining the best possible response to frontline treatment. 
What to do if the patient achieves CR before transplantation is still controversial 
(continuing chemotherapy versus transplantation). So far, transplantation is carried out in 
most cases, but the option has to be discussed with the patient. CR assessment is a poorly 
sensitive parameter, as minimal residual disease is present in most patients. If the patient 
does not achieve complete CR after transplantation, additional consolidation/maintenance 
therapy, including a second autologous transplantation, should be considered. 
 
Consolidation and maintenance therapy after transplantation 
Three separate phase 3 studies showed that thalidomide maintenance improves OS. 
Despite these findings, thalidomide is not routinely used for maintenance in many centers 
in consideration of its cumulative toxicity. Lenalidomide may offer the same advantages 
with less toxicity, and large randomized trials are now addressing its role in the post-
transplantation setting. Maintenance therapy is currently used when patients do not 
achieve CR after stem cell transplantation or in presence of genetic risk markers 
associated with very high risk of early relapse: in these cases, thalidomide and 
lenalidomide proved suitable. There are still insufficient data on bortezomib-based 
maintenance. It is unknown how long maintenance should be, but it is normally tailored 
on patient’s tolerance. Anticoagulation does not seem to be required in the maintenance 
setting 
[52 ]
. 
 
Recommendations (Grade C recommendation, level IV evidence unless stated) 
• Interferon (IFN)-α or single-agent corticosteroids cannot be routinely recommended as 
maintenance therapy (grade A, level Ib recommendation). In the allograft setting, IFN-α 
may be useful for patients who did not achieve a CR (grade B, level IIa); 
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• maintenance with thalidomide may improve EFS and OS in patients who did not 
achieve VGPR post high-dose chemotherapy and maintenance therapy could be 
considered (grade A, level Ia). Patients with deletion 13q may not benefit from it; 
• the dose of thalidomide should not exceed 150 mg (grade B, level IIa recommendation) 
and no recommendation can be made concerning the duration of thalidomide 
maintenance; 
• in the maintenance setting, routine anticoagulant prophylaxis is not required; 
• at present, there is no evidence of benefit for the use of thalidomide maintenance in 
elderly patients who did not undergo autologous transplantation; 
• the combination of steroids and thalidomide is not recommended in the maintenance 
setting due to increase toxicity and unclear benefit over thalidomide alone; 
• although promising data are emerging about the use of bortezomib or lenalidomide in 
the maintenance setting, long term are needed to recommend their use outside clinical 
trials 
[53]
. 
 
Patients unwilling or unsuitable for high-dose melphalan and transplantation 
In these patients, induction therapy (such as VTD, RVD, or CVD) can be prolonged to 
maximal response as an alternative to transplantation, followed by maintenance in those 
patients not achieving CR or at high risk for early relapse. 
Alternative regimens in younger patients, who do not undergo transplantation, could 
include alkylating agents in combinations, such as melphalan, prednisone, and 
bortezomib or cyclophosphamide, thalidomide, and dexamethasone, on the basis of drug 
availability. Less intensive treatment with lenalidomide and low-dose dexamethasone 
may be appropriate for patients not requiring a very rapid response to initial therapy and 
with low risk of early relapse on the basis of clinical features (e.g., low β-2 microglobulin, 
low LDH, absence of high-risk genetic features). 
In patients with significant co-morbidities precluding transplantation, also combination 
therapies could not be easily administered: in such patients less toxic approaches based 
on lenalidomide and low-dose dexamethasone could be employed, with the aim to obtain 
the best possible response with acceptable toxicity. Therapy efficacy in these conditions 
is unknown 
[52 ]
. 
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Relapsed and refractory disease 
Relapsed/refractory disease is defined in patients who achieve minor response or 
responses followed by relapse requiring salvage therapy, or in patients who experience 
progression within 60 days of their last chemotherapy. Subsequent treatment regimens 
result in progressively shorter response duration, which reflects the emerging drug 
resistance. The treatment choice depends on the previous schedules, the duration of the 
response obtained, and the potential side-effects that patient experienced. In general, 
patients with relapsed/refractory disease are preferentially treated with bortezomib, 
thalidomide, or lenalidomide. If these agents are no longer effective or unavailable, other 
treatment options (such as combination chemotherapy or high-dose dexamethasone) can 
be explored. Future trials will test combinations of novel drugs to increase effectiveness, 
overcome resistance, and reduce toxic effects, thus further improving patient outcome 
[5]
. 
 
Bone disease 
The treatment for osteolytic lesions consists in the use of bisphosphonates, radiotherapy, 
analgesics for bone pain and, rarely, vertebroplasty or surgical procedure for pathological 
fractures 
[9]
. Bisphosphonates (e.g. clodronate, pamidronate, zoledronate) are inhibitors of 
osteoclastic activity and may reduce tumor burden by changing BM microenvironment 
and promoting directly tumor cell apoptosis. They reduce the incidence of skeletal events, 
prevente hypercalcemia, relieve bone pain, and improve patient’s quality of life. Adverse 
effects include renal toxicity and jaw osteonecrosis in presence of scarse oral hygiene. 
Bone disease can also be treated with bortezomib, which inhibits osteoclasts and 
stimulates osteoblasts, thus increasing bone formation 
[3,9,10]
. 
 
33 
 
1.6 New therapeutic strategy in MM 
MM is still considered an incurable disease. Consequently, there are different new 
therapeutic strategies that are currently tested in preclinical and clinical studies in patients 
with MM. These agents have been classified according to the cellular mechanisms they 
specifically target: agents acting through cell-surface receptors (e.g, activators of cell-
death receptors, inhibitors of tyrosine-kinase receptors (TKR), and monoclonal antibodies 
against plasma-cell antigens); inhibitors of signalling pathways (e.g., nuclear factor kappa 
B (NFκB) inhibitors, farnesyl-transferase inhibitors (FTI), mitogen activated protein 
kinase (MAPK) inhibitors, mammalian target of rapamycin (mTOR) inhibitors, and AKT 
inhibitors); drugs interfering with the cell cycle (e.g., cyclin dependent kinase (CDK) 
inhibitors and aurorakinase inhibitors); inhibitors of the unfolded protein response (UPR) 
(e.g., heat-shock protein (HSP) inhibitors, proteasome inhibitors, and aggressome-
formation inhibitors) and epigenetic agents (e.g., hypomethylating compounds and 
deacetylase inhibitors). 
 
Agents acting on cell-surface receptors 
Direct activators of the extrinsic pathway of apoptosis 
Two members of the TNF-receptor superfamily have been studied as potential anti-
myeloma targets: the TNF-related apoptosis-inducing ligand (TRAIL) receptors (i.e. 
TRAIL-R1 and TRAIL-R2) and FAS (CD95). Several reports have shown the in vitro 
activity of the ligand TRAIL/APO2L against MM cell lines, ex vivo freshly isolated MM 
cells and in vivo human plasmocytomas xenografted into mice 
[54]
. 
 
Small-molecule inhibitors that target receptor tyrosine kinases 
A second interesting target for anticancer therapy is the group of TKRs. These receptors 
are very frequently overexpressed in cancer, including MM; consequently, several drugs 
have been designed to block their proliferative and antiapoptotic effects. Two examples 
are imatinib and dasatinib. The rationale for using these c-KIT or platelet-derived growth 
factor receptor (PDGFR) inhibitors is based on the evidence that about a third of patients 
with MM express c-KIT on plasma cell surface. 
Another group of these drugs are the FGF-3 inhibitors. The t(4;14) translocation, 
involving the FGF-3 gene, is present in 15% of MM patients and confers adverse 
prognosis. Studies, using the small-molecule inhibitor PD173074,44 or the inhibitor of 
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class III, IV, and V TKR (dovitinib), or another FGFR3 inhibitor (AB1010) have shown 
the capacity to inhibit FGFR3 autophosphorylation in cells carrying the translocation, 
resulting in plasma cell growth arrest and apoptosis. Different clinical studies has been 
started. In this study, we have tested a new FGFR3 inhibitor, as reported below. 
 
Another interesting target is VEGF because of its role in MM pathogenesis, as reported 
above. Several tyrosine-kinase inhibitors that target the three VEGFR are already 
available and have shown in vitro activity; in addition, a humanized monoclonal antibody 
against VEGF (bevacizumab) has already been tested in combination with lenalidomide 
and dexamethasone in 10 patients. Unfortunately, the expectations raised by the use of 
these agents have not been confirmed in the clinic so far, as the small-molecule 
antagonist pazopanib was ineffective in a phase II trial. Nevertheless, these agents might 
be used in combination with other drugs.  
 
IGF-1 is a relevant cytokine in the pathogenesis of MM. This receptor has been identified 
on most MM cell lines and ex vivo plasma cells, and its activation stimulates proliferation 
of MM cells and protects them from dexamethasone- or TRAIL-induced apoptosis. Some 
studies with monoclonal antibodies that block ligand binding are in progress for MM 
treatment 
[23]
. 
 
Monoclonal antibodies against surface antigens 
The crucial role for IL-6 receptor in plasma cells has been previously discussed. 
Nevertheless, clinical results with monoclonal antibodies against this receptor, used as 
single agents, are poor. Preliminary data with the combination of the monoclonal 
antibody CNTO 328 with bortezomib in 6 patients have shown five partial responses 
(two of them unconfirmed) 
[55]
. 
CD56 (neural cell adhesion molecule) is involved in the adhesion of MM plasma cells to 
BM stromal cells: the lack of this marker is associated with extramedullary spreading and 
tendency to poor prognosis. Around 75% of patients express this antigen on the surface of 
plasma cells. A new monoclonal antibody, HuN901-DM1, which covalently binds to 
CD56 and, once internalized, releases the novel cytotoxic maytansinoid DM1, has been 
developed with promising in vitro and in vivo preclinical activity. A phase I study is 
exploring its clinical activity in patients with CD56
+
 refractory MM 
[56]
. CD56 is also 
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expressed by NK cells, and, therefore, this molecule might theoretically hamper the anti-
myeloma immune response, but there are not sufficient data so far. 
CS1 (cell surface 1 antigen) is a glycoprotein expressed at high levels in MM plasma 
cells, CD8
+
 lymphocytes, and NK cells, and is important for the adhesion of plasma cells 
to stroma. A humanized monoclonal antibody (HuLuc 63) has been generated against this 
antigen with interesting preclinical activity; nevertheless, no responses have been 
observed when used as single-agent in the first 7 treated patients 
[57]
. 
CD40 is expressed on cells with high proliferative activity and in all antigen-presenting 
cells. In MM cell lines, the monoclonal antibody anti-CD40 (SGN-40) induced apoptosis 
by growth-inhibitory signaling, antibody-dependent cellular cytotoxicity and antibody-
dependent cellular phagocytosis. In a phase I trial that included 32 MM patients, only 
transient drops in the M-component or stable disease were obtained 
[58]
. 
 
Molecules interfering with different signaling pathways 
NFκB inhibitors 
NFκB is a transcription factor involved in the regulation of genes that participate in cell 
cycle and apoptosis control. Interaction of myeloma cells with BM microenvironment 
triggers NFκB-dependent transcription of cytokines, such as IL-6. Studies have shown 
specific mutations in genes that regulate the NFκB pathway in up to 80% of MM patients. 
Drugs that inhibit NFκB activation, such as inhibitors of the upstream kinase IKKβ, have 
shown anti-myeloma activity in preclinical models. Also bortezomib targets this pathway, 
and a correlation has been noted between the clinical response to this agent and TNF-
receptor-associated factor 3 (TRAF3) function. The latter is a protein that negatively 
regulates NFκB activity. (Figure 5) 
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Figure 5. Ubiquitine-proteasome pathway and NF-kB.  
 
Farnesyl-transferase inhibitors 
N-RAS and K-RAS mutations are frequent in advanced MM and are associated with 
adverse prognosis. The use of drugs to inhibit RAS farnesylation in MM patients seems 
to be an attractive approach, especially in patients with RAS mutations. The preliminary 
findings of a phase II trial with the FTI inhibitor tipifarnib are not encouraging, because 
stable disease was achieved only in few patients. It has in vitro synergy with other agents, 
such as bortezomib, but no clinical data have been reported so far. 
MAPK inhibitors 
The use of P38 MAPK inhibitors (e.g., SCIOS-469) resulted in the inhibition of MM cell 
proliferation and decrease of IL-6 and VEGF secretion; these inhibitors show synergy 
with bortezomib. A phase II trial with SCIOS-469 in 62 patients with relapsed MM 
showed stable disease in 24% of the 28 patients receiving the drug in monotherapy. When 
combined with bortezomib, 9 of the 34 patients achieved partial response, 2 showed 
minor response and 3 stable disease. Nevertheless, these responses might be mainly due 
to bortezomib and not to the P38 inhibitor or the combination. Another drug acting on 
this pathway is the MAPK-kinase inhibitor AZD 6244, which is effective against MM 
tumor cells and improves myeloma bone disease in preclinical models. 
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mTOR inhibitors 
mTOR is a downstream target of PI3K/AKT and mediates phosphorylation of proteins 
responsible for the regulation of protein synthesis and expression of multiple proteins, 
including D-type cyclins and c-MYC. On the basis of the in vitro findings, mTOR 
inhibitors, such as rapamycin and its analogue temsirolimus, are currently under clinical 
assessment in MM, both alone and in combination with lenalidomide. 
PI3K/AKT inhibitors. 
Perifosine is an oral bioactive new alkylphospholipid that inhibits AKT and induces in 
vitro and in vivo cytotoxicity in human MM cells; it is synergistic with other agents, such 
as dexamethasone, doxorubicin, melphalan, and bortezomib. These data provided the 
rationale for the ongoing clinical trial with perifosine alone and with dexamethasone, 
bortezomib and/or lenalidomide 
[23]
. 
 
Agents interfering with the cell cycle 
In MM, the control of cell-cycle deregulation is of particular relevance due to the nearly 
generalized over-expression of cyclins in MM plasma cells. Two families of agents have 
been employed: 
CDK inhibitors 
CDK activity is regulated by cyclins; as mentioned above, cyclins D1, D2, or D3 are 
deregulated in virtually all MM patients. Moreover, gene expression profiling and clinical 
follow-up have shown differences between the distinct cyclin-D subgroups. As this 
deregulation seems to be a unifying molecular abnormality in this disease, attempts to 
inhibit cyclin-D activity by targeting its CDK partners have been carried out with MM 
cells in vitro. Several of these CDK inhibitors resulted effective, by inducing not only cell 
cycle arrest, but also apoptosis. Clinical trials with these inhibitors will start soon. 
Aurora-kinase inhibitors 
Aurora kinases are proteins involved in mitotic process. Preclinical studies have shown 
that aurora-kinase inhibitors determine hyperdiploidy and myeloma cell death 
[59,60]
. 
 
Inhibitors of the UPR 
The UPR is responsible for the detection of misfolded proteins and the coordination of 
their disposal. UPR proper activity is necessary to maintain cell homoeostasis, especially 
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in case of neoplastic cells, due to their increased metabolism and protein turnover. MM 
cells secrete large amounts of Ig, which need to be correctly folded by the chaperone 
system. If this process fails, the misfolded proteins have to be eliminated by the two main 
garbage-disposal systems of the cell: the proteasome and the aggresome. Their blockade 
results in the accumulation of Ig and other toxic proteins in the cytoplasm, and cell death. 
HSP inhibitors 
The proper activity of HSPs is crucial for the survival of MM cells, not only because they 
require appropriate chaperon machinery to manage the large amounts of proteins 
synthesized, but also because they need this system to stabilize survival signaling key-
proteins, such as AKT, MEK and NFκB. In fact, HSP27, HSP70 and HSP90 are 
overexpressed in MM. The use of HSP inhibitors leads to cytotoxic intracellular 
accumulation of misfolded proteins with subsequent cell death. In vitro studies have 
shown anti-myeloma activity of HSP inhibitors and a synergistic effect with bortezomib. 
After phase I studies that confirmed their activity, a phase II trial of tanespimycin plus 
bortezomib was started, with preliminary good responses 
[61]
. 
In these work we used two new HSP90 inhibitors NO and N2, by Novartis Oncology, as 
reported below. 
New proteasome inhibitors 
As previously mentioned, the proteasome inhibitor bortezomib, together with the 
immunomodulatory drugs, has changed the clinical course of MM. Other proteasome 
inhibitors have been tested with the aims to increase the potency and bioavailability, 
lower toxicity profile and, eventually, facilitate the administration route. Carfilzomib is 
one of this new group of proteasome inhibitors with potent in vitro activity by inhibiting 
the chymotrypsin-like activity. 
Other proteasome inhibitors have been developed, such as NPI-0052, an oral inhibitor 
that blocks in vitro the three catalytic activities of the proteasome (trypsinlike, 
chymotrypsin-like, and caspase-like); phase I studies with this drug are ongoing. Finally, 
other agents are in the first stages of development, such as the oral inhibitor CEP-
18770
[62,63]
. 
Inhibitors of aggresome formation 
The simultaneous inhibition of the two cellular garbage-disposal systems, the proteasome 
and the aggresome, by the histone deacetylase [HDAC]-6 inhibitor tubacin resulted in a 
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synergistic increase in cytotoxicity of MM cell lines and ex vivo isolated fresh cells; 
however, no clinical data has been reported so far 
[23]
. 
 
Epigenetic agents 
HDAC inhibitors 
Many tumors, including MM cells, show enhanced HDAC activity resulting in the 
decrease in DNA transcription, especially of tumor-suppressor genes, thus leading to pro-
oncogenic conditions. Treatment with HDAC inhibitors can revert this deacetylated 
pattern, leadingto the final differentiation or apoptosis of MM cells through different 
mechanisms. Pan-DACi have been shown to have multiple effects in tumor cell lines, 
such as decreased oncoprotein expression (e.g., Bcr-Abl, HER-2), angiogenesis and 
tumor cell motility and invasion, as well as induction of apoptosis and cell cycle arrest. A 
present, several clinically relevant HDAC inhibitors are available and clinical trials with 
HDAC alone and in combination with other anti-myeloma agents are in progress 
[23]
. 
In this study we have tested the effect of a histone deacetylase inhibitors, as reported 
below. 
Hypomethylating agents 
5-Azacytidine is active against MM cells and its clinical efficacy is currently under 
assessment in a phase II trial. Combinations of hypo-methylating agents and HDAC 
inhibitors will be explored to verify whether the simultaneous targeting of both epigenetic 
pathways may result in antitumoral synergism 
[23]
. 
 
Other agents 
Plitidepsin (aplidin) 
Aplidin is an antitumor agent derived from the marine tunicate Aplidium albicans. 
Although its target has not been defined yet, the involvement of Jun N-terminal kinase 
and P38 pathways has been shown in aplidin-induced apoptosis in MM. Moreover, this 
compound is synergistic in vitro with several anti-myeloma agents.  
Arsenic trioxide 
The rationale for using arsenic trioxide in MM is based on its multifaceted effects on MM 
cell lines and ex vivo fresh MM cells. A phase II trial in heavily pretreated patients with 
relapsed or refractory MM showed minor responses or stabilization of the M-component. 
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Glutathione has been shown as inhibitor of arsenic trioxide-induced cell death. As 
ascorbic acid can decrease glutathione concentrations, its combination with arsenic 
trioxide as well as with dexamethasone would seem appropriate, because they use 
different proapoptotic pathways. The activity of this drug should be further investigated, 
because it is active in patients resistant to bortezomib, melphalan or both 
[23]
. 
 
On the basis of a written consensus agreement with Novartis-Oncology company, we 
tested in this study the efficacy and toxicity in vitro (on MM cell lines) and in vivo (in a 
mouse MM model) of 5 new molecules: 
Hyston deacetilasi (HiDAC) inhibitor (L9): it is a pan-DACi that has been studied in 
many hematological and solid malignancies, including Hodgkin’s lymphoma, MM, acute 
myeloid leukemia (AML), and myelodysplastic syndromes (MDS). In preclinical studies, 
L9 has shown nanomolar activity in different hematological malignancies and synergy 
with chemotherapeutic drugs, demethylators, proteasome inhibitors, and other agents. 
Phase Ib/II studies of L9, as monotherapy and in combination with chemotherapy and/or 
targeted therapy, are ongoing in relapsed/refractory Hodgkin's lymphoma (HL), MM, 
AML/MDS and other hematological malignancies. Phase III trials are ongoing with 
global enrollment in relapsed MM (PANORAMA-1) and post–transplant HL 
maintenance (PATH). 
N0 and N2: they are novel, non-geldanamycin derivative HSP90 inhibitors. N2 is orally 
bioavailable. Both in vitro and in vivo models indicate that they have significant 
antitumor activity in a wide range of mutated and wild-type cancer cell lines, primary 
tumor cells and animal models of cancer, including MM, gastric cancer, non-small-cell 
lung carcinoma (NSCLC), hepatocellular cancer, sarcoma, and breast cancer. Phase I and 
II studies in hematological malignancies and in solid tumors, including breast cancer and 
MM, are ongoing with N0. N2 is being investigated in Phase I clinical trials in patients 
with advanced solid tumors.  
FGFR3 inhibitor (T8): it is orally bioavailable and inhibits VEGFR and FGFRs. Phase 
III trial in renal cell carcinoma, and phase II trial in advanced breast cancer, relapsed MM 
and urothelial cancer are ongoing with this molecule. 
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Human neutralizing antibody, anti-DKK1 (N80): Preclinical studies support the 
hypothesis that N80 promotes bone formation and inhibits tumor-induced osteolytic 
disease.
 
N80 is currently in Phase I/II clinical trials in MM. 
[http://www.novartisoncology.com] 
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2. 5T MOUSE MODEL 
 
In our study we have used a mouse cell line of MM called 5T33vtMM, which derives 
from a murine myeloma developing in BM of C57BL/KaLwRij mice. 
In 1974 Jiri Radl and Carel Hollander examined by agar gel electrophoresis 800 sera 
from BALB/c, C57BL/Ka, CBA and C3H mice ranging in age from 1 to 30 months. They 
found that only in C57BL/Ka 50% of mice by 24 months of age had homogeneous Ig (H-
Ig) bands in the β2-γ region. The incidence of these H-Igs increased with age and could 
be enhanced by neonatal thymectomy or immunization with various antigens given 
without adjuvants. In BALB/c mice they found only a scarce incidence of spontaneously 
H-Igs, while in athymic BALB/c/nu/nu mice they were found in 63% of animals by 12 
months of age. Dr. Radl transplanted BM from affected old mice into young irradiated 
recipients (2x10
6
 bone marrow or 2.5x10
6
 spleen cells were injected intravenously) and 
obtained the propagation of H-Ig clones. 
During these studies, the occasional onset of progressive plasma cell tumors was 
observed: they produced large amounts of monoclonal Ig and grew serially in a high 
percentage of recipients, following intravenous transplantation. These mice also 
developed osteolytic bone lesions. It was estimated that 0.5% of ageing C57BL/KaLwRij 
mice developed aggressive plasma cell tumors in BM, defined as 5T myelomas. This 
model is now considered a cellular surrogate of human MM. 
Of 5T tumors, 5T33 and 5T2 are mostly used. 5T2 tumor is morphologically 
heterogeneous and contains lymphoid cells as well as plasma cells; its growth is more 
restricted to BM and displays less progressive evolution. 5T33 tumor cell line were 
derived, growing in vitro with (5T33vvMM) or without (5T33vtMM) adherent stromal 
cell layer. If injected intravenously, 5T33 tumor variants induce paralysis at 35-40 days 
after injection, as well as infiltration of BM, liver, spleen and lymph nodes, and osteolytic 
lesions. Unlike the induced peritoneal plasmocytomas (such as Sp6), 5T tumors do not 
have either c-myc activating t(12;15), as shown by the absence of rearranged myc bands, 
or t(6;15). 5T plasma cells express isoforms of CD44-adhesion molecules V6, V7 and 
V10, which are critical for the adhesion of 5T cells to BM endothelium.  
In conclusion, 5T transplantable MM model resembles human MM in several aspects: 
myeloma occurred spontaneously, the frequency of development of the disease is age-
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related, tumor load can be assessed by paraproteinemia and the concentration of normal 
Ig is low in the serum (Table 3) [37, 64, 65]. 
 
Table 3. Characteristics of models of plasma cell tumor development (Adapted by 
Potter et al.) 
 
Model system Species Genetics c-myc 
activation 
by CT 
Microenvironment of 
origin 
IL-6 Anti-
apoptotic 
factors 
Peritoneal PTCs induced 
by pristane* 
Mouse ++, BALB/c is 
hypersusceptible 
Yes Chronic inflammatory 
oil granuloma 
Inflammation 
cells and 
macrophage 
IL-6 
IL-6 transgenic Mouse Suspected, not yet 
defined 
Yes Lymphonodes and 
medullary cords 
Trangene IL-6 
Eμ-ν-abl-transgenic Mouse Not yet defined Yes Lymphonodes and bone 
marrow 
? ν-abl-
transgenic 
ABL/MYC retrovirus Mouse + No LP-GI tract, 
lymphonodes and spleen 
? ν-abl 
Bcl2/BclXL Mouse ? Yes Peritoneal cavity ? transgene 
5T Mouse C57BL/KaLwRij No Bone marrow ? ? 
MGUS,  
Multiple Myelom 
Human ? No Bone marrow Stromal cells ? 
 
 
CT: chromosomal translocation; GI: gastrointestinal; IL: interleukin;  *Other poorly metabolized materials 
are effective as well 
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AIMS OF STUDY 
 
In this study, we examined the therapeutic potential of five new drugs in MM treatment. 
We analyzed their effect in vitro on different human and mouse myeloma cell lines. In 
particular, we performed cytotoxic assay and, in case of reduction in cell viability, we 
assessed whether this effect was associated with the induction of apoptosis. 
We also explored the effects of these new potential drugs in vitro and in vivo in a mouse 
preclinical model of myeloma, 5T33vtMM, cell line, tumorigenic in the syngenic 
C57BL/KaLwRij mouse. Thus, we could evaluate at different time points the changes of 
tumor burden in treated mice, as compared to untreated, myeloma-bearing control 
animals. 
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MATERIALS AND METHODS 
 
1. Cell lines 
In this study, we have used different myeloma cell lines: human cell lines were 
RPMI-8226, U-266, KMS-11; mouse cell line was 5T33vtMM. RPMI-8226, KMS-11, 
5T33vtMM were maintained in RPMI 1640 medium (Gibco Invitrogen Corporation, San 
Diego, CA, USA) supplied with glutamine 1mM (Biochrom AG, Berlin, Germany) and 
10% heat-inactivated fetal bovine serum (FBS; Euroclone, Pavia, Italy). U-266 was 
supplied with 15% of FBS. All cell lines were incubated at 37°C and 5% CO2. 
 
2. Drugs solution and formulation 
All the molecules were supplied by Novartis Pharmaceuticals (Basel, 
Switzerland). For in vitro studies, N0, N2 and T8 were dissolved in dimethyl sulfoxide 
(DMSO) at stock concentration of 10 mM, while L9 was dissolved at stock concentration 
of 30 mM. The stock solutions were aliquoted and stored at -20°C. N80 was freshly 
dissolved before use. For in vivo studies, all the drugs were freshly dissolved before use, 
according to drug company’s instructions. 
 
3. Cell viability assay 
In the cytotoxic assays cells were seeded in 90 µl of RPMI medium (Sigma-
Aldrich, Milan, Italy) without red fenol, with 10% FBS at a density of 0.2x10
5
 cells/well 
in flat-bottomed 96-well plates (Falcon, Becton Dickinson, Lincoln Park, NJ, USA). The 
molecules were added to wells at serial dilutions. In details: N80: 4, 2, 1, 0.5 and 0.25 
ng/ml; N0, N2 and L9: 1000, 333, 111, 55, 27, 13.8, 4.6, 1.5 nM; T8: 5000, 2500, 1250, 
750, 375, 187.5, 93.7, 46.8 nM. Total volume of each well was 100 µl and all drug 
concentrations were added in triplicate for each experiment. Plates were incubated for 24 
and 48 hours at 37°C and 5% CO2. Cytotoxicity assays were performed by using the vital 
standard 2,3-bis[2-Methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxyanilide 
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inner salt (XTT) colorimetric assay. 10 µl of a 1.5-mg phenazin (Sigma-Aldrich, Milan, 
Italy)/ml and phosphate-buffered saline (PBS) were added to 10 ml of 5-mg XTT (Sigma-
Aldrich, Milan, Italy)/ml RPMI medium stock solution. This freshly prepared mixture 
was sterilely filtered, and 40 µl were added to each well containing the cells to be tested. 
Absorption was measured at 450 nm after 2 hours of incubation at 37°C with 5% CO2. 
Three independent experiments were performed for each condition. 
 
4. Evaluation of apoptosis in vitro 
Cells were treated with different concentrations (12.5, 20, 200 nM) of N0, N2 and 
L9 for 48 hours. Annexin V (Ann-V)/propidium iodide (PI) apoptosis assay was 
performed according to manufacturer’s protocol (Roche diagnostics, Milan, Italy). Cells 
were gently mixed and the fractions of apoptotic (Ann-V
+
/PI
-
), dead (Ann-V
+
/PI
+
) and 
alive (Ann-V
-
/PI
-
) cells were measured by flow cytometry (BD-Pharmigen, Milan, Italy). 
Active Caspase-3 was quantified by using homogenous caspase assay kit, according to 
manufacturer’s protocol (BD-Pharmingen, Milan, Italy) and measured by using 
FACSCalibur flow cytometer (BD-Pharmigen, Milan, Italy) and FlowJo analysis 
software. Three independent experiments were performed for each condition. 
 
5. In vivo experiments 
 C57BL/KaLwRij mice (Harlan Laboratories, Belgium) were bred in the animal 
facility of the University of Verona. Two month-old male and/or female mice were 
injected intravenously (i.v.) through the tail vein with 0.5×10
6
 5T33vtMM tumor cells 
resuspended in 0.1 ml PBS. The dose of 0.5×10
6
 cells is tumorigenic in vivo in 100% of 
syngeneic animals and gave rise to paraplegia in mice in 45-50 days. Tumors grew in 
BM, spleen and liver. 
Tumor bearing mice were divided into different groups to receive different 
treatments, starting at day +10 from tumor injection. In details: mice in group 1 (n=6) 
were treated with vehicle (PBS) intraperitoneally (i.p.); group 2 (n=8) were treated with 
N0 50 mg/Kg i.p- once a week; group 3 (n=8) were treated with N0 50 mg/Kg i.p. twice a 
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week for 2 week with a week of resting; group 4 (n=8) received N2 10 mg/Kg per os 
(p.o.) once a week; group 5 (n=8) received N2 10 mg/Kg p.o. twice a week for 2 week 
with a week of resting; group 6 (n=8) were treated with L9 10 mg/Kg i.p. 5 days/week 
and group 7 (n=8) were treated with L9 20 mg/Kg i.p. 5 days/week for 2 week with a 
week of resting. Two different treatment schedule were used for N80: both the groups 
were treated with N80 10 mg/kg i.p. twice/week, but group 8 (n=8) started treatment on 
day +0 (preventive schedule), while group 9 (n=8) started on day +10 (curative schedule). 
Mice were sacrificed when they developed paraplegia. If signs of pain and fatigue 
became evident in the animals earlier, they were sacrificed immediately. All in vivo 
experiments were part of Research Protocols authorized by the Italian Ministry of Health: 
Decreto n. 199/2008-B and 14/2012-B,. 
 
6. Evaluation of tumor burden 
Tumor burden was measured in mice by determining the concentration of 
paraprotein and VEGF in serum, which were collected at specific time point (+31 and 
+45 days after tumor cell injection). ELISA assay was used to quantify the levels of 
murine IgG2b (BETHYL Laboratories.Inc, Montgomery, TX, USA ) and VEGF (R&D 
System, Minneapolis, MN, USA). Serum samples were diluted prior to test (dilution 
1:10.000) for ELISA IgG2b, and required 5-fold dilution for ELISA VEGF. The range of 
sensitivity of the ELISA IgG2b assay was 0.34-250 ng/ml.  
 
7. Histomorphometry 
Three mice for each group, at day +45 from tumor injection, were sacrificed for 
histomorphometric analysis. They were injected with demeclocycline 25 mg/Kg 
subcutanuosly (s.c.) 14 and 13 days before sacrifice, and with calcein 10 mg/Kg s.c. 4 
and 3 days before sacrifice. 
The right tibiae were removed, dissected to remove soft tissue, and fixed in 70% 
reagent alcohol. The samples were embedded undecalcified in methyl-methacrylate resin 
(Merck 800590, Darmstadt, Germany). Bone sections were cut by using a microtome 
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(Polycut S, Leica Microsystems, Wetzlar, Germany) equipped with a carbide-tungsten 
blade, stained with Goldner’s stain and toluidine blue, and mounted on microscope slides 
for histomorphometric measurements. Some sections were left unstained for the 
measurement of fluorescent labeling. The sections were obtained from three different 
levels of the methyl-methacrylate block, each separated by a thickness of 250 µm. 
Histomorphometric results were calculated as the mean of the values obtained from the 
three different levels as an approximation of a 3-D evaluation. This also avoids 
replicating the sampling of any single bone remodeling unit. 
Measurements were performed by means of an image analysis system consisting of 
epifluorescent microscope (Leica DM2500, Leica Microsystems, Wetzlar, Germany) 
connected to a digital camera (Leica DFC420 C) and a computer equipped with a specific 
software for histomorphometric analyses (Bone 3.5, Explora Nova, La Rochelle, France).  
The area analyzed was restricted to the trabecular bone of the secondary spongiosa area 
between 2 and 4 mm distal to the growth plate-metaphyseal junction
[66]
. 
Histomorphometric parameters are reported in accordance with the ASBMR Committee 
nomenclature 
[67]
.  
Thickness results were adjusted for the obliquity of sections by multiplying by π/4 [67]. As 
to the assessment of trabecular microarchitecture, trabecular number (Tb.N), trabecular 
separation (Tb.Sp; μm), and trabecular thickness (Tb.Th; μm) were measured. After 
skeletonization, the trabecular network was evaluated by measuring the connections 
between nodes (points at which three or more trabeculae joined), connection branches 
(struts), terminal or free-ends branches (termini) and by calculating Total Skeletonized 
Structure Length (TSL), number of nodes (N.Nd/TV), and nodes/termini ratio (Nd/Tm), 
as previously described 
[68]
.  
In addition, indirect parameters of microarchitecture were assessed: Marrow Star Volume 
(MSV; N/mm
3
), that is the mean volume of all the parts of an object that can be 
unobscured in all the directions from a point inside the object 
[69]
; Fractal Dimension (D), 
which describes how an object fills space with relation to its structure. This parameter 
permits to evaluate bone structural anisotropy 
[70]
. 
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8. Statistical analysis 
When applicable, results are presented as mean ± standard deviation. Annexin-V, 
Caspase-3 and ELISA tests were analyzed by analysis of variance (ANOVA) with the 
post hoc Tukey test for intra-group comparison. Survival analysis has been carried out 
using the method developed by Kaplan and Meiers, and the log-rank test to compare 
survival. Differences were considered statistically significant for P values ≤ 0.05. 
Statistical analysis was performed using GraphPad Prism 5 (GraphPad Software, Inc., 
San Diego, CA, USA). 
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RESULTS  
 
1. Effect of N80, T8, L9, N0 and N2 on MM cells in vitro 
Concentration-dependent anti-survival activity of N80, T8, L9, N0, and N2 was assessed 
in vitro on a panel of human (RPMI-8226, U-266, KMS-11) and mouse (5T33vtMM) 
myeloma cell lines by using the XTT assay (see Materials and Methods) at 24 and 48 
hours.  
 N80 was tested on all cell lines at different concentrations (4, 2, 1, 0.5 and 0.25 
ng/mL) for 24 and 48 hours of incubation. As expected, no effect of N80 on cell survival 
was observed on treated cells as compared to controls, either after 24 (data not shown) or 
48 hours (Figure 6 and Table 4A). 
 
 
Figure 6. N80 has no cytotoxic effect on MM cells in vitro:  XTT test at different concentrations of N80 
in medium culture after 48 hours of incubation. The percentage of viable cells is on y axis, while the 
different concentrations of N80 (ng/mL) are on x axis. Mean value ± standard deviation (n=3). 
 
 T8 effect was assessed on 5T33vtMM cell line at concentrations ranging from 5,000 
nM to 20 nM; we found a reduction in cell survival only for high concentrations of the 
molecule, with median inhibition concentration (IC50) value of 4,315 nM after 48 hours 
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of incubation (Figure 7A, B and Table 4B). No inhibition was found after 24 hours of 
treatment (data not shown).  
 
 
Figure 7. T8 has cytotoxic effect on 5T33vtMM cells only at high doses in vitro: XTT test on 
5T33vtMM at different concentrations of T8 in medium culture after 48 hours of incubation. The 
percentage of viable cells is on y axis, while the different concentrations of T8 (nM) are on x axis. 
Normalized data in linear graph (A) and transformed in logarithmic graph (B). Mean value ± standard 
deviation (n=3). 
 
 The human myeloma cell lines and the mouse 5T33vtMM cell line were exposed to 
N0 at concentrations ranging from 0.15 nM up to 1,000 nM for 24 hours (data not shown) 
and 48 hours (Figure 8). After 48 hours IC50 values raging from 2.15 to 7.88 nM were 
observed in all myeloma cell lines (Table 4C). The maximum decrease in myeloma cell 
viability varied from 100% in the sensitive cell lines 5T33vtMM to 23% in RPMI-8226 
(Table 4C). 
 
Figure 8. A linear dose-response effect is observed treating MM cells with increasing amounts of N0: 
XTT test at different concentrations of N0 in medium culture after 48 hours. The percentage of viable cells 
is on y axis, while the different concentrations of N0 (nM) are on x axis. Normalized data in linear graph 
(A) and transformed in logarithmic (B). Mean value ± standard deviation (n=3). 
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N2 activity on human and mouse myeloma cell lines was tested for concentrations 
ranging from 0.15 nM up to 1,000 nM for 24 (data not shown) and 48 hours (Figure 9). 
After 48 hours IC50 values ranging from 3.63 to 26.72 nM were observed in all myeloma 
cell lines (Table 4D). The maximum decrease in myeloma cell viability was very similar 
for all cell lines, reaching 1% viability in RPMI-8226 and the total abrogation in the 
sensitive cell lines 5T33vtMM, KMS-11 and U-266 (Table 4D). 
 
Figure 9. N2 is effective in reducing the viability of MM cells in vitro after 48 hours: XTT test at 
different concentrations of N2 in medium culture at 48 hours. The percentage of viable cells is on y axis, 
while the different concentrations of N2 (nM) are on x axis. Normalized data in linear graph (A) and 
transformed in logarithmic (B). Mean value ± standard deviation (n=3). 
 
 Finally, we tested L9 on 5T33vtMM, RPMI-8226, U-266 and KMS-11 at 
concentrations ranging from 1,000 nM to 0.15 nM for 24 (data not shown) and 48 hours. 
We found a reduction in cell activity for different concentrations of L9 in different cell 
lines, with IC50 values ranging from 3.63 nM for 5T33vtMM to 25.72 nM for RPMI-8226 
after 48 hours of incubation (Figure 10A and B, Table 4E). The maximum decrease in 
myeloma cell viability varied from total abrogation in the sensitive cell lines 5T33vtMM, 
RPMI-8226 and U-266, to 27% viability in KMS-11 (Table 4E). 
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Figure 10. L9 reduces viability of MM cells in different manner in vitro: XTT test at different 
concentrations of L9 in medium culture at 48 hours. The percentage of viable cells is on y axis, while the 
different concentrations of L9 (nM) are on x axis. Normalized data in linear graph (A) and transformed in 
logarithmic (B). Mean value ± standard deviation (n=3). 
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Table 4: IC50 and minimum viability values for N80 (A), T8 (B), N0 (C), N2 (D), L9 (E) in MM cell 
lines. Cells were cultured in the presence of 0.25-4 ng/mL of N80, 20-5,000 nM of T8, 0.15-1,000 nM of 
N0, N2 and L9 for 48 hours and viability was determinated using XTT assay. 
Cell line IC50 (nM) 
Min. cell viability  
(% of control) 
A) N80   
             KMS-11 Not reached 70% 
             RPMI-8226 Not reached 65% 
             U-266 Not reached 100% 
            5T33vtMM Not reached 75% 
B) T8   
            5T33vtMM 4315 1% 
C) N0   
             KMS-11 7.88 7% 
             RPMI-8226 7.68 23% 
             U-266 6.6 3% 
            5T33vtMM 2.15 0% 
D) N2   
             KMS-11 20.79 0% 
             RPMI-8226 26.72 1% 
             U-266 19.76 0% 
            5T33vtMM 3.63 0% 
E) L9   
             KMS-11 10.73 27% 
             RPMI-8226 9.797 0% 
             U-266 31.27 0% 
            5T33vtMM 4.585 0% 
 
N2, N0 and L9 were the most potent compounds with nanomolar IC50 values and for this 
reason they were used for further studies. 
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2. N0, N2 and L9 induce cell apoptosis in vitro 
In XTT test, N0, N2 and L9 reduced the viability of MM cells in all cell lines. To assess 
whether their effect was either cytostatic or cytotoxic, these molecules were analyzed for 
apoptosis induction by using Ann-V/PI analysis and Caspase-3 protein expression after 
48 hour culture with drugs at different concentrations (12.5, 20 and 200 nM). 
N0 (Figure 11, Table5 and B): N0 was capable of exerting a statistically significant 
(P=0.05) pro-apoptotic effect already at 12.5 nM dose in all cell lines, as compared to 
untreated RPMI-8226, KMS-11, U-266 and 5T33vtMM (n=3). The effect was not dose-
dependent, as there were not statistically significant differences with the dose of 25 nM 
(n=3) and 200 nM (n=3), as compared to 12.5 nM. 
 
Table 5: Studies of apoptosis after culture with different doses of N0 for 48 hours. A) percentage of 
alive cells (Annexin-V negative and PI negative); B) percentage of Caspase-3 positive cells. Mean value  ± 
standard deviation (n=3). 
 
A) N0: % Ann-V-/PI- cells (alive) B) N0: % caspase-3+ cells  
nM RPMI-8226 KMS-11 U-266 5T33vtMM RPMI-8226 KMS-11 U-266 5T33vtMM 
NT 72.23±2.3 70.87±0.25 94.67±1.16 83.2± 1.65 17.84 ± 1.23 16.33±1.78 10.44±0.55 5.61±0.53 
12.5 15.97±1.01  29.53±2.03 69.17±1.35 1.35 ± 0.11 60.47± 5.25 58.33 ±2.77 57.03±2 80.43±3.51 
25 18.4±0.51  15.6±1.04 68.8±2.1 0.6 ± 0.31 64.63±1.4 55.17 ±3.38 66.37±5.72 84.8±3.27 
200 17.9±1.76 16.23±1.45 67.63±0.6 1.04  ± 0.32 70.2±1.3 53.74±1.3 66.27±6.57 82.5±5.42 
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Figure 11. N0 inhibits the survival of MM cells in vitro, activating apoptosis. (A): Annexin-V/PI test: a 
representative experiment on 5T33vtMM cells. After 3 days, the presence of N0 at all concentrations 
strongly inhibited the growth of 5T33vtMM in vitro, as shown by the increase of double-positive (Ann-
V+/PI+) cells. (B): Mean percentage of viable MM cells (Ann-V-/PI-) at 48 hours (n=3). The percentage of 
viable cells is on y axis, while the different concentrations of N0 (nM) are on x axis. Mean value ± standard 
deviation. As compared to MM cell lines cultured alone, the presence of N0 at different concentrations 
exerted a statistically significant pro-apoptotic effect. This effect was appreciable in all 4 cell lines (human 
and mouse). (C): Caspase-3 test: a representative experiment on 5T33vtMM cells. The presence of N0 at 
all concentrations induced the expression of Caspase-3. (D): Mean percentage of Caspase-3+cells at 48 
hours (n=3). The percentage of Caspase-3+ cells is on y axis, while the different concentrations of N0 (nM) 
are on x axis. Mean value ± standard deviation. Reduction of cell survival was due to activation of 
apoptotic pathway through the expression of Caspase-3 (*= P<0.05; **= P<0.01; ***= P<0.001). 
 
N2 (Figure 12, Table 6A and B): culture with N2 was capable of exerting a statistically 
significant pro-apoptotic effect already at dose of 12.5 nM for U-266 and 5T33vtMM 
(P=0.01), but not for KMS-11 and RPMI-8226. An increase of apoptotic cells, as 
compared to untreated cells, was obtained at 20 nM dose for KMS-11 (P=0.05) and only 
at 200 nM dose for RPMI-8226 (P=0.01). The effect was dose-dependent, with the 
statistically significant linear reduction of alive cells along with increasing N2 dose in 
culture medium (P=0.01 for all conditions) (Table 3A). We could observe the same 
effect on the induction of Caspase-3 expression (Table 6B and Figure 12).  
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Table 6: Studies of apoptosis after culture with different doses of N2 for 48 hours. A) percentage of 
alive cells (Annexin-V negative and PI negative); B) percentage of Caspase-3 positive cells Mean value  ± 
standard deviation (n=3). 
 
A) N2: % Ann-V-/PI- cells (alive) B) N2: % caspase-3+ cells  
nM RPMI-8226 KMS-11 U-266 5T33vtMM RPMI-8226 KMS-11 U-266 5T33vtMM 
NT 74.23±0.23 67.7±3.74 92.87±0.06 83.17± 1.50 22.4±4.6 10.8±3.2 8.14±0.6 6±0.6 
12.5 62.27±28.66 61.87±1.39 78.87±1.55 73.4 ± 2.08 31.6±7.3 9.7±1.5 28.5±2.3 17.8±4.3 
25 64.07±2.13 57.37±2.81 74.33±0.67 60.97 ± 1.01 51.3±3.6 15.4±3.8 36.2±4.9 32.7±3.9 
200 28.67±3.28 14.87±4.82 55.73±1.16 4.64  ± 0.56 59.2±3.4 62.9±0.7 47.7±2.1 80.5±5.3 
 
 
 
Figure 12. N2 inhibits the survival of MM cells in vitro, activating apoptosis. (A): Annexin-V/PI test: a 
representative experiment on 5T33vtMM cells. After 3 days, the presence of N2 at different concentrations 
strongly inhibited the growth of 5T33vtMM in vitro, as shown by the increase of double-positive (Ann-
V+/PI+) cells. (B): Mean percentage of viable MM cells (Ann-V-/PI-) at 48 hours (n=3). The percentage of 
viable cells is on y axis, while the different concentrations of N2 (nM) are on x axis. Mean value ± standard 
deviation. As compared to MM cell lines cultured alone, the presence of N2 at different concentrations 
exerted a statistically significant pro-apoptotic effect. This effect was appreciable in all 4 cell lines, for 
concentration of 200 nM, but only in 5T33vtMM and U-266 for 12.5 nM and 25 nM. (C): Caspase-3 test: 
representative experiment on 5T33vtMM cells. The presence of N2 at all concentrations induced the 
expression of Caspase-3. (D): Mean percentage of Caspase-3+ cells at 48 hours (n=3). The percentage of 
Caspase-3+ cells is on y axis, while the different concentrations of N2 (nM) are on x axis. Mean value ± 
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standard deviation. Reduction of cell survival was due to activation of apoptotic pathway, by the expression 
of Caspase-3 (*= P<0.05; **= P<0.01; ***= P<0.001). 
 
L9 (Figure 13, Table 7A and B): culture with L9 was capable of exerting a statistically 
significant pro-apoptotic effect already at dose of 12.5 nM for all cell lines (P=0.01). The 
effect was dose-dependent for all cell lines: we could observe a statistically significant 
linear reduction of alive cell along with increasing L9 dose in culture medium for all 
conditions with U-266 and 5T33vtMM (P=0.01), while there were no differences 
between 12.5 and 25 nM for RPMI-8226 and KMS-11. A significant difference was 
observed for 200 nM as compared to 12.5 nM (P=0.05 for KMS-11 and P=0.01 for 
RPMI-8226) and 25 nM (P=0.05 for both cell lines) (Table 7A). We could observe the 
same effects in the induction of Caspase-3 expression (Table 7B and Figure 13).  
 
Table 7: Studies of apoptosis after culture with different doses of L9 for 48 hours. A) percentage of 
alive cells (Annexin-V negative and PI negative); B) percentage of Caspase-3 positive cells. Mean value  ± 
standard deviation (n=3). 
A) L9: % Ann-V-/PI- cells (alive) B) L9: % caspase-3+ cells  
nM RPMI-8226 KMS-11 U-266 5T33vtMM RPMI-8226 KMS-11 U-266 5T33vtMM 
NT 68.47±0.47 73.2±0.95 90.07±0.11 71.63±0.46 14.13±0.59 24.06±0.69 8.95±0.69 14.,44±1.12 
12.5 6.72±1.47 19.97±1.42 64.13±3.11 39.03±1.15 54.03±7.34 65.3±3.22 44,7±0.53 55,5±3.35 
25 4.76±0.83 18.67±1.8 51.4±0.86 3.23±0.24 73.97±0.80 58.3±2.15 60.27±2.98 78.37±6.31 
200 2-21±0.29 14.87±4.82 55.73±1.16 4.64 ±0.56 71.4±2.74 55.33±4.20 77.67±4.08 84.03±0.83 
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Figure 13. L9 inhibits the survival of MM cells in vitro, activating apoptosis. (A): Annexin-V/PI test: a 
representative experiment on 5T33vtMM cells. After 3 days, the presence of L9 at different concentrations 
strongly inhibited the growth of 5T33vtMM in vitro, as shown by the increase of double-positive (Ann-
V+/PI+) cells. (B): Mean percentage of viable MM cells (Ann-V-/PI-) at 48 hours (n=3). The percentage of 
viable cells is on y axis, while the different concentrations of L9 (nM) are on x axis. Mean value ± standard 
deviation. As compared to MM cell lines cultured alone, the presence of L9 at different concentrations 
exerted a statistically significant pro-apoptotic effect. This effect was appreciable in all 4 cell lines (human 
and mouse) (C): Caspase-3 test: a representative experiment on 5T33vtMM cells. The presence of L9 at all 
concentrations induced the expression of Caspase-3. (D): Mean percentage of Caspase-3+ cells at 48 hours 
(n=3). The percentage of Caspase-3+ cells is on y axis, while the different concentrations of L9 (nM) are on 
x axis. Mean value ± standard deviation. Reduction of cell survival was due to apoptotic pathway activation 
through the expression of Caspase-3 (*= P<0.05; **= P<0.01; ***= P<0.001). 
 
 In summary, studies on 5T33vtMM have shown the cytotoxic activity of N0, N2 
and L9. XTT test has detected the almost complete reduction of viable cells with high 
doses of drugs, and IC50 values of 2.15 nM for N0, 3.63 nM for N2, and 4.585 nM for L9 
(Table 4 and Figure 14A). This effect is correlated with the induction of apoptosis, as 
demonstrated by Annexin-V/PI analysis. As compared to 5T33vtMM cultured alone 
(79.67  6.15% viable cells, n=9), the presence of 12.5 nM of drug was capable of 
exerting a statistically significant pro-apoptotic effect: 1.35 ± 0.11% alive cells for N0 
(n=3; P=0.01), 73.4 ± 2.08% for N2 (n=3; P=0.05) and 39.03±1.15%, (n=3; P=0.01) for 
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L9. N0 is significantly more effective in inducing apoptosis than N2 (P=0.01) and L9 
(P=0.01); and 5T33vtMM cells are more sensible to L9 than N2 (P=0.01) (Table 5, 6 
and 7, and Figure 14B). Further analysis have shown that cell death occurred through 
caspase-3 activation (Figure 14C). 
 
Figure 14. 5T33vtMM is sensible to N0, N2 and L9 in vitro. (A): XTT test, linear data. The percentage of 
viable cells is on y axis, while the different concentrations of the drugs (nM) are on x axis. Mean value ± 
standard deviation. (B): Annexin-V/PI test: mean percentage of viable MM cells (Ann-V-/PI-) at 48 hours 
(mean value ± standard deviation) at 12.5 nM of N0, N2 and L9. (C): Caspase-3 test: mean percentage of 
Caspase-3+ cells at 48 hours (mean value ± standard deviation) with 12.5 nM of N0, N2 and L9. N0 and L9 
induced a significant reduction of viable cells as compared to untreated samples, activating apoptosis. 
5T33vtMM is more susceptible to N0 and L9 as compared to N2 at low concentration (*= P<0.05; **= 
P<0.01; ***= P<0.001). 
 
3. Treatment with N0, N2, L9 and N80 reduces M-component production in vivo 
To evaluate tumor development from 5T33vtMM injected in C57BL/KaLwRij, we 
measured IgG2b level, the paraprotein produced by neoplastic cells, by using ELISA 
assay on serum samples collected at different time points. At day +31 from cell injection 
no differences were found in mice treated with all drugs, as compared to untreated mice 
(data not shown). In details, the levels of serum IgG2b was 5.34  9.97 g/L in untreated 
mice (n=6), 5.07 1.78 g/L in mice treated with L9 20 mg/Kg/day for 5 days/week (n=7), 
4.09 0.98 g/L in mice treated with N0 50 mg/Kg twice/week (n=4), and 5.30 0.64 g/L 
in mice treated with N2 10 mg/Kg twice/week (n=7). 
At day +45, we found a reduction of IgG2b serum levels in mice treated with N80, N0, 
N2 and L9, as compared to untreated mice (n=3) (36.03± 12.88 g/L). In particular, N0 
was tested at two different doses (50 mg/kg i.p. once a week and 50 mg/kg i.p. twice a 
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week): both treatments started at day +10 from tumor cells injection and led to a 
significant reduction in IgG2b serum levels of mice treated with N0 (once a week 
schedule: 6.78± 1.80 g/L; P<0.01, n=3; double week schedule: 9.58± 8.84 g/L; P<0.05, 
n=3), without differences between the two schedules (Figure 15). 
 
Figure 15: treatment with N0 reduces tumor burden at day +45: ELISA assay of IgG2b (g/L) in serum 
of mice untreated and treated with N0 50 mg/Kg i.p. once a week or twice a week. Mean value ± standard 
deviation (n=3). (*= P<0.05; **= P<0.01; ***= P<0.001). 
 
Similarly, N2 was tested at two different schedules of treatment: 10 mg/kg orally 
once a week and 10 mg/kg orally twice a week. Both schedules started at day +10 from 
tumor cells injection. We found a significant reduction in IgG2b serum levels in mice 
treated with N2 (once a week schedule: 5.24± 4.10 g/L; P<0.001, n=3; double week 
schedule: 4.08± 0.98 g/L; P<0.001, n=3), without differences between the two schedules 
(Figure 16). 
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Figure 16: treatment with N2 reduces tumor burden at day +45: ELISA assay of IgG2b (g/L) in serum 
of mice untreated, treated with N2 10 mg/Kg orally once a week or twice a week. Mean value ± standard 
deviation (n=3). (*= P<0.05; **= P<0.01; ***= P<0.001). 
 
L9 was tested at two different schedules of treatment: 10 mg/kg i.p. 5 days a week 
and 20 mg/kg i.p. 5 days a week. Both schedules started at day +10 from tumor cells 
injection. No differences were found in IgG2b serum levels of mice treated with L9 at 
low dose (27.63± 5.48 g/L, n=3), while the highest dose was effective (5.34± 0.58 g/L 
n=3) as compared to control group (P<0.001) and low dose schedule (P<0.01) (Figure 
17). 
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Figure 17: treatment with L9 reduces tumor burden at day +45 at a dose of 20 mg/kg for 5 days a 
week: ELISA assay of IgG2b (g/L) in serum of mice untreated, treated with L9 10 mg/Kg or 20 mg/kg i.p. 
5 days/week Mean value ± standard deviation (n=3). (*= P<0.05; **= P<0.01; ***= P<0.001). 
 
N80 was tested at two different schedules of treatment: 10 mg/kg i.p. twice a week 
for preventive treatment (started at day +0 from tumor cells injection) and therapeutical 
treatment (started at day +10). No differences were found in IgG2b serum levels of mice 
treated with N80 using the therapeutical schedule (24.79± 6.69 g/L, n=3), while the 
preventive schedule was effective (7.05± 1.40 g/L n=3) as compared to control group 
(P<0.01) and therapeutical schedule (P<0.05) (Figure 18). 
 
Figure 18: treatment with N80 reduces tumor burden at day +45 in a preventive schedule: ELISA 
assay of IgG2b (g/L) in serum of mice untreated, and treated with N80 10 mg/Kg i.p twice a week 
according to preventive and therapeutical schedules. Mean value ± standard deviation (n=3). (*=P<0.05; 
**= P<0.01; ***= P<0.001). 
 
In summary, treatment with N0 and N2 was effective in lowering IgG2b serum 
levels at low doses, while L9 required high doses. Once a week schedule of N0 and N2 
has similar effects, while is significantly more effective than L9 at low dose (P<0.01 for 
N0 and P<0.001 for N2). All drugs reduced M-component levels when used at high dose, 
with no differences among the various schedules. 
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4. Treatments with N0, N2, L9 and N80 reduce serum VEGF in vivo 
The level of VEGF was measured in mice serum collected at day +45 by using 
ELISA test. We found a statistically significant reduction in VEGF levels in mice treated 
with all drugs as compared to controls. In details, the levels of VEGF were: 76.35± 6.69 
pg/ml (n=3) in tumor bearing mice not receiving treatment; 43.22± 14.43 pg/ml in mice 
treated with N0 50 mg/Kg i.p. once a week (P<0.01, n=3); 47.06± 12.47 pg/ml in mice 
treated with N2 10 mg/Kg orally once a week (P<0.05, n=3); 37.22± 4.08 pg/ml  in mice 
treated with L9 10 mg/Kg i.p. 5 days at week (P<0.01, n=3); 26.79± 3.15 pg/ml in mice 
treated with N80 10 mg/Kg i.p. twice a week in a preventive schedule (P<0.01, n=3) and 
38.49± 8.93 pg/mlin mice treated with N80 10 mg/Kg i.p. twice a week in a therapeutical 
schedule (P<0.001, n=3)  (Figure 19). 
No significant differences were observed among the various schedules. 
 
Figure 19: all the drugs reduce VEGF levels at day +45: ELISA assay of VEGF (pg/mL) in serum of 
mice untreated, treated with N0 50 mg/Kg i.p. once a week, N2 10 mg/Kg orally once a week, L9 10 
mg/Kg i.p. 5 days at week, N80 10 mg/Kg i.p. twice a week in a preventive and therapeutical schedule. 
Mean value ± standard deviation (n=3). (*= P<0.05; **= P<0.01; ***= P<0.001). 
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5. Treatments with L9 improved bone architecture of mice injected in vivo with 
5T33vtMM cells  
Tumor bearing mice showed significant reduction in trabecular bone volume, 
thickness and number of trabeculae. Moreover, we could observed an increased osteoclast 
activity expressed as the extent and depth of erosion surfaces and number of active 
osteoclasts. There was also reduction of osteoblastic activity, of osteoid parameters (data 
not shown) and we could detect an abnormal microarchitecture.  
The administrations of N80, N0, N2 were not able to prevent bone damage (trabeculae 
thin, non-interconnected, large gaps bone marrow and localization of disease, -data not 
shown). Otherwise, the administration of L9, already at low dose, showed the ability to 
preserve the trabecular microarchitecture and a partially osteoblastic activity. This effect 
was significantly increased when mice were treated with L9 higher dose, showing an 
organization trabecular most represented, with trabeculae more closed to each other and 
with a thickness significantly higher compared to untreated mice (Figure 20). 
 
 
Figure 20: L9 influence bone architecture in vivo in 5T33MM model. Histomorphometric section of 
mice injected i.v. with 0.5×106 5T33vtMM cells at day 0 and treated with: L9 10 mg/Kg i.p. 5 days a week 
(A) or 20 mg/kg i.p. 5 days a week (B).  
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6. Treatments with N0, N2, L9 and N80 do not modify the overall survival of mice 
injected in vivo with 5T33vtMM cells  
Distinct Groups of C57BL/KaLwRij mice were injected i.v. with 5T33vtMM cells. 
On day +10, all animals started treatment with the different drugs. Median OS was not 
significantly improved by the administration of the different treatments. In details: 
median OS was 44.5 days in control animals (range: 38-53 days, n=6), 45 days in mice 
treated with N0 50 mg/Kg i.p. once a week (range 37-52 days, n=8) and 22.5 days  twice 
a week (range 11-31 days, n=8) (Figure 21A). We observed increasing toxicity in mice 
treated with high dose schedule, with necrosis at the injection site (Figure 22). 
Treatment with N2 induced a median OS of 39 days (range 31-47 days, n=8) for 
mice receiving 10 mg/Kg orally once a week, and 54 days (range 17-69 days, n=8) for 
mice receiving a twice a week schedule (Figure 21B). 
Treatment with L9 induced a median OS of 42 days (range 31-47 days, n=6) for 
mice receiving 10 mg/Kg i.p. 5 days a week and 45 days (range 38-56 days, n=6) for 
mice receiving 20 mg/Kg i.p. 5 days a week (Figure 21C). 
Treatment with N80 induced a median OS of 46 days (range 42-55 days, n=6) for 
mice receiving 10 mg/Kg i.p. twice a week in a preventive schedule, and 41 days (range 
38-56 days, n=6) for mice receiving the therapeutical schedule (Figure 21D). 
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Figure 20: None of the drugs influence OS in vivo in 5T33MM model. OS of mice injected i.v. with 
0.5×106 5T33vtMM cells at day 0 and treated with: N0 50 mg/Kg i.p. once a week or twice a week (A), N2 
10 mg/Kg orally once a week or twice a week (B), L9 10 mg/Kg i.p. 5 days a week or 20 mg/kg i.p. 5 days 
a week (C), N80 10 mg/Kg i.p. twice a week in a preventive and therapeutical schedule (D).  
 
 
 
Figure 21: N0 high dose causes necrosis at the injection site. Mice injected i.v. with 0.5×106 5T33vtMM 
cells at day 0 and treated with N0 50 mg/Kg i.p. twice a week developed necrosis at the site of injection, 
already after 2 doses. 
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DISCUSSION 
 
Multiple myeloma is still an incurable disease, although new therapeutical strategies have 
become available in the last years. New treatments based on either biologic drugs, such as 
thalidomide and lenalidomide, or NFkB inhibitors, such as bortezomib, have improved 
patients’ quality of life by reducing bone pain, anemia, fatigue and complication related 
to the presence of M-component. In addition, they have increased the event free survival, 
although often without improving the overall survival, especially when used as 
monotherapy. Thus, novel therapeutic targets and synergistic combinations with 
appropriate anti-myeloma agents are urgently needed. 
In particular, the large amount of studies on MM microenvironment, biology of 
neoplastic plasma cell and multistep progression from MGUS to MM facilitates the 
development of new compounds with either direct cytotoxic effect on myeloma cells, or 
specific interference with tumor microenvironment. 
In this study, in collaborations with a drug company (Novartis Farma S.p.A.), we tested 
five new molecules with different action mechanisms: nuclear inhibitors (L9); growth 
factor receptor inhibitors (T8); intracellular inhibitors (N0, N2); and monoclonal 
antibodies with potential anti-cancer effects (N80). The results of the experiments can be 
shown only partially until the end of the project, because of the confidentiality agreement 
with Novartis Farma S.p.A. 
The in vitro experiments have permitted to demonstrate that the mouse cell line 
5T33vtMM and human cell lines (RPMI-8226, U-266, KMS-11) are sensible to drugs in 
a similar manner. This finding is quite relevant, as it shows that these drugs have a 
general effect on plasma cell biology, regardless the species of origin. 
L9 is a HiDAC inhibitor with well known effects on MM cell lines. Deacetylase (DACs) 
are enzymes specialized in removing acetyl groups from their target proteins, which can 
be histone- and non-histone proteins. The use of this kind of drugs in MM is supported by 
the evidence that there is a general pattern of deacetylation in neoplastic cells that could 
be reverted by the use of HiDAC inhibitors. So far, phase III randomized trials are in 
progress to assess whether the combination of HiDAC inhibitors with either bortezomib 
or lenalidomide plus dexametasone is superior to standard protocols currently used for 
69 
 
relapsed/refractory MM patients 
[71]
. By adding L9 to culture medium, we confirmed the 
reduction of cell viability in all human ad mouse cell lines in vitro. This effect was related 
to the induction of apoptosis, as shown by Annexin-V test and the expression of Caspase-
3 in all death cells. For in vivo studies, we divided mice in two groups, one treated with 
10 mg/kg/five days week and one with 20 mg/kg/5 days week. We collected serum of 
mice at days +45 after injection for the assays. We observed a decrease in serum M-
component (IgG2b) levels for high doses, but not for the 10 mg/Kg dose, while serum 
VEGF level was already reduced with lower dose of the agent. Thus, a better definition of 
the therapeutical window of L9 has to be done. 
T8 blocks multiple signalling pathways activated by FGFRs, inhibits proliferation and 
causes a strong reduction in mammary tumor outgrowth and lung metastasis formation. In 
addition, it inhibits VEGFR) and PDGFR 
[72]
. Theoretically, T8 may have a specific 
application in MM, as activating mutations of FGFR3 occurs in about 10% of patients 
with t(4;14) MM and play an important role in the progression of t(4;14) (p16;q32) MM. 
This chromosome translocation identifies MM with poor prognosis, in particular when 
treated with melphalan and thalidomide/lenalidomide, while bortezomib appears to 
abrogate the early mortality, even if the poor prognosis is not completely overcome. 
However, the absence of FGFR3 expression in about 25% of patients with t(4;14) MM 
cases suggests that the persistent expression of FGFR3 is important, at least in some 
patients 
[73]
. In our study we did not find any cytotoxic activity of T8 on 5T33vtMM cells, 
probably because this mouse cell line has not the mutation enhancing FGFR3 activity. 
Consequently, we decided not to proceed with other experiments with this molecule. 
N0 and N2 are Hsp90 inhibitors. These molecules have shown potent anti-cancer activity 
in preclinical studies of leukemia, lymphoma and selected solid tumors, where they 
showed synergistic effects with either conventional cytotoxic drugs, such as etoposide, 
taxol and cytarabine, or target therapies such as imatinib and rituximab. 
[74]
. In particular, 
the promising preclinical data obtained with N0 supported the start of clinical phase I 
trials in patients with solid tumors. 
[75]
. By using N0 and N2, we observed a different 
cytotoxic effect on the cells lines, depending on drug concentration and cell type, with 
IC50 values in the low nanomolar range. Annexin-V assay demonstrated that significant 
apoptosis may be induced with N0 in all cell lines low doses (12.5 nM), in absence of 
dose-effect curve. By contrast, N2 addition led to significant late and early apoptosis at 
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12.5 nM dose only using U-266 and 5T33vtMM cerll lines, but not KMS-11 and RPMI-
8226, which required at least 25 nM concentration to observe significant cell death, as 
shown by Caspase-3 expression. In addition, N2 pro-apoptotic effect was dose-
dependent, differently from N0. Thus, N0 and N2 seem to act differently, regardless their 
common inhibitory effect on Hsp90. 
In vivo studies with N0 and N2 were based on two different administration protocols, 
once or twice a week, to test the kinetics of action of both molecules. At day +45 after 
tumor injection, we found a significant reduction in tumor burden in all treated mice as 
compared to controls, as measured by serum M-component (IgG2b) and VEGF levels, 
and with both the molecules and treatment schedules. However, we did not find any 
advantage from using higher doses of both drugs, rather signs of toxicity (necrosis in the 
side injection) in mice treated with N0 twice/week. N2 was administered orally, with no 
apparent toxicity along dose increase. In summary, N0 and N2 seem to be promising in 
terms of efficacy and their use has to be further investigated. 
N80 is a fully humanized, anti-DKK1 monoclonal antibody, with high affinity and 
neutralizing effect on both human and mouse DKK1. In MM, the overexpression of 
DKK1 by plasma cells inversely correlates with lytic bone disease, because it inhibits 
osteoclasts. N80-based clinical trials are in progress both in relapsed and high-risk 
asymptomatic MM 
[76]
. As expected, we did not find any direct in vitro cytotoxic effect of 
N80 on 5T33vtMM cells after both 24 and 48 hours of incubation; however, in 
consideration of its mechanism of action on osteoclasts, we tested its clinical 
effectiveness in vivo. We performed experiments with two treatment schedules: early 
treatment, administered the same days of neoplastic cell injection (preventive schedule), 
and late treatment, at days +10 from tumor injection (therapeutical schedule), thus 
mimicking N80 use in clinical trials. We found a significant reduction in IgG2b serum 
levels only by using preventive schedule, while VEGF reduction occurred following both 
treatments, although less evident, in a non statistically manner, with the preventive 
schedule. Thus, our data confirm other studies 
[77]
 and show that the anti-DKK1 antibody 
does not act directly on MM cells, but may interfere with bone microenvironment leading 
to bone formation and indirect inhibition of tumor growth. 
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Although all the treatment schedules tested in this study did not modify significantly the 
overall survival of tumor bearing mice, the reduction in tumor burden observed with 
some of these new molecules (L9, N2, N0 and N80) has to be anyway considered a good 
result for myeloma treatments based on single agents. In fact, most of the new molecules 
tested so far were not effective when used alone. Consequently, our results give support 
to plan new therapeutic strategies by using different doses, administration schedules and 
combinations of L9, N2, N0 and N80. Different therapeutical approaches might 
eventually influence OS, such as increasing the dose of single drugs, combining new 
molecules with high-dose steroids, or melphalan, or bortezomib and 
thalidomide/lenalidomide. Moreover, different MM mouse models could be used: for 
instance, 5T33vtMM cells could be injected into SCID Rag2-/- γ chain -/- mice, which 
are profoundly immunodeficient mice capable of accepting human cells without any sign 
of rejection. In this case, developing MM would have the same growth kinetics than 
using C57BL/KalwRij mice (personal observation), with the advantage to evaluate 
indirectly the role in the response to anti-myeloma treatment of recipient immune system, 
which completely lacks in SCID Rag2-/- γ chain -/- mice. 
Another experimental approach will be to assess the efficacy of different drugs on fresh 
plasma cells, once collected ex vivo from BM samples of MM patients and positively 
selected by immunosorting for CD38+. This way, the sensitivity to drugs could be tested 
in vitro in a personalized manner for each single patient with MM at diagnosis. 
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